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ABSTRACT OF THESIS: 
 
EXAMINING THE NEUROPROTECTIVE PROPERTIES OF 3-
DIMETHOXYBENZYLIDENE-ANABASINE (DMXB-A) IN A THIRD TRIMESTER 
CHRONIC ETHANOL EXPOSURE MODEL IN RATS 
 
Excitotoxicity caused by ethanol (ETOH) withdrawal (EWD) is highly 
detrimental to the developing brain. Targeting this excitotoxicity has been shown to be a 
promising approach for improving outcome following developmental ETOH exposure. 
Activation of nicotinic acetylcholine receptors (nAChR), in the central nervous system 
can be protective against EWD. We examined the ability of DMXB-A, a α7 nAChR 
agonist, to reduce neurotoxicity caused by EWD in the hippocampus. To test this, an 
organotypic hippocampal slice culture was used. Slices were exposed to ETOH (100mM) 
or control medium. After 10 days, the slices were treated with DMXB-A (1, 3, or 10uM) 
during EWD. After 24 hours of EWD cell damage in the CA1, CA3, and dentate gyrus of 
the hippocampus was analyzed.  The combination of EWD and NMDA produced 
increased toxicity compared to controls in the CA1 region, DMXB-A attenuated this 
effect, suggesting that DMXB-A was protective against EWD neurotoxicity in vitro. 
These findings are exciting because this drug is currently in clinical trials for a variety of 
CNS conditions and so has significant translational potential. Further research is 
necessary to better understand the extent of its neuroprotective properties and to 
determine its ability to reduce behavioral deficits following prenatal ethanol exposure. 
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Ethanol Use, Abuse, and Outcomes  
Background 
Alcohol is one of the most commonly used drugs in the western world, with an 
estimated 87% of individuals (18 years of age or older) reporting that they had consumed 
alcohol at some point in their lifetime, 71% in the last year, and 56 % in the last month 
(NIAAA, 2014). Though ethanol consumption alone is most often not problematic, 
approximately 25% of the population (18 years or older) have reported binge drinking 
(defined as 3 drinks for women and 4 drinks for men in two hours) in the last month and 
about 7% reporting that they had engaged in heavy drinking (5 or more drinks in one 
occasion on 5 days in a given month) (NIAAA, 2014).  These drinking patterns 
sometimes lead to alcohol use disorders which can be problematic for the individual and 
those around them. Ethanol consumption during pregnancy in women who have an 
alcohol use disorder can have many negative effects on the newborn. The effects of 
ethanol consumption during pregnancy on infant development have been reported for 
many years. Some of the earliest examples of ethanol consumption during pregnancy can 
be seen in ancient Greek and Roman beliefs, stating that being intoxicated at the time of 
reproduction would lead to the birth of a “damaged child” (Calhoun & Warren, 2007).  
Clinical descriptions of the association between maternal drinking and the development 
of learning/attention disorders and physical deformations have been reported for several 
decades.  The first published report was in 1968 by a French physician and his colleagues 
who described a set of characteristics in children who had been exposed to ethanol in 
utero (Lemoine et al., 1968).  In the United States, the syndrome was first identified by 
Jones and Smith, who described a pattern of malformations in the offspring of mothers 
who had consumed ethanol during pregnancy. This research led to the observation that 
infants who were exposed to ethanol in utero could have a characteristic set of 
abnormalities which has come to be called Fetal Alcohol Syndrome (FAS) (Jones & 
Smith, 1973). In order to be diagnosed with the disorder the child has to have (a) 
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evidence of a characteristic pattern of facial anomalies which can include short palpebral 
fissures and abnormalities in the premaxillary zone (i.e. flat upper lip, flattened philtrum, 
and flat midface), (b) evidence of pre- and/or postnatal growth retardation (born small 
and fail to thrive i.e. low birth weight), and (c) evidence of   CNS damage (microcephaly, 
mental retardation, or neurobehavioral deficits) (Stratton, 1996). Because prenatal ethanol 
effects vary in severity, with FAS being the most extreme case, a spectrum was 
developed to aid in the description of children who were only marginally affected by 
ethanol’s effects during gestation (Hoyme, et al. 2004). These guidelines that encompass 
fetal ethanol effects without the full diagnosis of FAS are known as Fetal Alcohol 
Spectrum Disorders (FASDs). These guidelines state that an infant exposed to ethanol 
during pregnancy does not have to demonstrate all of the characteristic symptoms of FAS 
to be considered to have an alcohol-related disorder (Jones, 2011). This aids families of 
children affected by ethanol exposure by providing special services to those affected 
(Jones, 2011).  Due to better understanding of the disorder and its diagnosis, estimates of 
the population affected by FAS/FASD have increased. Estimates taken in the United 
States suggest that the prevalence of FAS is about 0.5-2.0 cases for every 1000 births 
(National Institutes of Health., 2013). Recent studies have also shown that misdiagnoses 
in children in foster/adoptive care is also very prevalent, where 80% of children who met 
the criteria for diagnosis in the fetal alcohol spectrum had previously not been diagnosed 
as having been exposed to prenatal alcohol (Chasnoff et al., 2015).  Although exact 
numbers on the prevalence of FASDs in the population are unknown, using conservative 
estimates from 2012, there may be as many as three times as many cases of FASDs as 
FAS (Centers for Disease Control, 2012). Healthcare and other indirect costs associated 
with the disorder have put the likely annual cost of FASDs in the US as high as $3.6 
billion (Olson, et. al., 2009). Drinking during pregnancy is the leading preventable cause 
of mental retardation in modern civilization, and because this has remained an issue the 
need for treatment is vital.  
Outcomes of FASDs 
 Fetal Alcohol Spectrum Disorders are difficult to diagnose because the 
morphological changes commonly found in more severe forms of FAS/FASDs may not 
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be present in all patients, sometimes leading to missed diagnoses or no diagnoses at all. 
Treatment for these disorders is also difficult because no medication currently exists for 
either FAS/FASDs. Because of this, physicians commonly use medication used to treat 
behavioral disorders like attention deficit/hyperactivity disorders (ADD/ADHD). 
Children living with FAS/FASDs typically have some behavioral/learning deficits along 
with social/economic difficulties later in life (Bishop et al., 2007). Other characteristic 
deficiencies in children with FAS and occasionally FASDs include prenatal and postnatal 
growth problems (Mattson & Riley, 1998; Mattson et al., 1998 ; Riley et al., 2011).  
Because there is now an accepted spectrum of severity with FASDs, ranging from minor 
to severe, diagnoses of the disorder can be challenging. This is especially so in children 
displaying minimal facial malformations, which is commonly associated with less 
exposure to ethanol during gestation (Mattson et al., 2010). However, these less severe 
cases do demonstrate deficits common to more severe FAS, including problems with 
executive functioning, motor coordination, spatial learning, attention, and hyperactivity 
(Jones, 2011; Mattson & Riley, 1998).  Some cognitive and behavioral assessments have 
been able to aid in diagnoses of children who had a history of ethanol exposure in utero, 
as they showed impairments in working memory, planning, and cognitive flexibility 
which are characteristic of FASD (Mattson et al., 2010). However, this is made difficult 
because these cognitive deficits can oftentimes resemble characteristic symptoms of 
ADHD. As many as 94% of children exposed to relatively large amounts of prenatal 
alcohol could be diagnosed with attention deficit hyperactivity disorder (Peadon & 
Elliott, 2010). Children with FAS/FASDs can also have impaired social functioning. This 
problem can cause children with the disorder to experience negative life situations 
including problems at home, school, and eventually in the workplace (Kully-Martens et 
al., 2012). These issues associated with FASD present a multitude of problems for the 
individual, their families and society. 
Binge Drinking: Possible Mediator of FASD’s  
Drinking alcohol during pregnancy is associated with many problems.  After a 
mother consumes alcohol it crosses the placental barrier and within minutes of the onset 
of a drinking episode, the fetal alcohol content can equal that of the maternal blood 
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(Paintner, Williams, & Burd, 2012). Additionally, amniotic fluid retains a peak alcohol 
concentration for a longer period of time due to the decreased ability of the fetus to either 
metabolize or transfer the ethanol back to the mother, who can rapidly metabolize the 
chemical, resulting in a prolonged exposure period (Nava-Ocampo et al., 2004).  
Research on quantity, timing, and pattern of consumption of alcohol during pregnancy 
and its effects on the fetus in animal models has been studied extensively to help create 
models of fetal ethanol exposures effects (for review see Painter, 2012). However, 
research suggests that certain patterns of consumption may be more harmful than others 
and that exposure at different time points during development differentially affect certain 
regions of the brain and other organ systems.   
A characteristic pattern of consumption for many alcoholics is binge drinking 
(defined above). In an animal model looking at prenatal development in the rat, binge 
drinking led to greater elevations in blood alcohol content leading to higher peak periods 
of ethanol exposure for the developing fetus (Livy et al., 2003).  With binge drinking, 
there is often a binge pattern of drinking followed by periods of withdrawal.  This pattern 
has been linked to more severe deficits in populations of children with FASDs (Paintner 
et al., 2012).  The amount of alcohol consumed may not be as important, in terms of 
overall detrimental effects, as the pattern of drinking by the mother.   
Alcohols Effects on the Developing Brain 
The developing fetus is in a constant state of growth and change. Such changes 
encompass the development of many structures including the brain and nervous system. 
These systems are highly susceptible to the neurotoxic effects of ethanol during their 
development (Rodier, 1994). Some of ethanol’s effects on the CNS include: disruption in 
cellular metabolism, an increase in hypoxic events, the creation of free radicals, an 
inhibition of DNA methylation, and membrane fluidization (For review see: Alfonso-
Loeches & Guerri 2011; Berman & Hannigan 2000; Eckardt et al., 2006; Goodlett & 
Horn, 2001 & 2005; Jones 2011, Olney, J. 2004; West et al., 1994).  Each of these are 
detrimental to the survival of a developing cellular network. One critical period of growth 
is the third trimester of pregnancy; it is a time of rapid division and migration of neural 
cells into their constituent networks. This period is often referred to as the brain growth 
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spurt (Dobbing & Sands 1979).  Exposure to alcohol during this time can be especially 
detrimental, affecting neuronal migration, synaptogenesis, myelination, dendritic 
aborization, histone methylation and other aspects of brain maturation and differentiation 
(For review see: Goodlett et al., 2005; Guo et al., 2011; Painter et al., 2012).  Regions of 
the brain that undergo extensive development during this time, e.g., cerebellum and 
hippocampus, have been shown to be particularly sensitive to ethanol exposure during the 
third trimester (Alfonso-Loeches & Guerri, 2011), demonstrating the importance of 
timing.   
Changes in the brain 
 Children with an FASD show characteristic disabilities that can be related back to 
changes in the CNS. Through the advancement of neuroimaging techniques it has 
become possible to study brains of children with an FASD.  Using magnetic resonance 
imaging (MRI) there are several distinct brain regions that are more typically affected by 
ethanol exposure than others in both FAS and FASDs. Some structures affected have 
shown decreases in white matter compared to typically developing peers. Archibald and 
colleagues (2001) found in 12 children diagnosed with FAS that cerebellar gray and 
white matter was significantly reduced when compared to patients without FAS 
diagnoses. In children with FASDs there were differences in fiber tracts like the corpus 
callosum compared to control participants (Fryer et al., 2009). Other regions affected by 
prenatal ethanol exposure include the posterior cingulate, temporal lobe, and specific 
areas of the frontal, occipital, and parietal lobes in both FAS and FASD (Riley & McGee, 
2005; Mattson et al., 1994; Spottiswoode et al., 2011). Furthermore, moderate to heavy 
exposure to ethanol has been shown to cause a decrease in myelination and thus cellular 
signaling in both human studies and animal models (Fryer et al., 2009; Sowell et al., 
2008). Further understanding of the effects of ethanol exposure has led to more accurate 
development of diagnostic tests related to behavior and cognition that have been used in 
both human FASDs and animal models.  
 Of particular interest for this proposal are the effects of fetal ETOH (ethanol) 
exposure on the hippocampus. Imaging studies using young children diagnosed with FAS 
have not shown dramatic changes structurally to the hippocampus (Archibald et al., 2001; 
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Riley & McGee, 2005), but because so many of the behavioral deficits associated with 
FASDs are learning and memory oriented, it suggests that this structure may be partially 
responsible for the deficits. Although the changes related to this structure may not be 
apparent at the macro level it may be the case that cellular and molecular functioning in 
this structure may be altered by ethanol exposure during development. The CA1 region of 
the hippocampus appears to be especially sensitive to ethanol’s effects during late 
prenatal and early postnatal development. Tran & Kelly (2003) reported there was cell 
loss in the CA1 region of the hippocampus when ethanol was administered during the 3
rd
 
trimester equivalent in rodents.  Livy and colleagues (2003) found similar results when 
ethanol was administered during the 3
rd
 trimester equivalent in the CA1. However, they 
also found a significant reduction in cell numbers and density in the CA3 region of the 
hippocampus. Previous studies using in-vitro hippocampal cultures have shown that 
ETOH exposure followed by withdrawal in the hippocampus drastically reduces survival 
of the cells in several regions of the hippocampus (Barron et al., 2008; de Fibre, 2003 & 
2005, Li et al., 2000 & 2002; Prendergast et al., 2000 & 2004; Wilkins et al., 2006). This 
research has stimulated study into the cellular mechanisms related to ETOH exposure and 
withdrawal in the hippocampus and how novel compounds may mitigate this damage.  
Modeling FAS/FASDs in Animals 
 The use and development of animal models in studying FASDs is a critical 
component and powerful tool in the process of understanding the disorder (for review 
see, Patten et al., 2014). Some of the most important components to consider are the 






 trimester), the level of 
intoxication and the administration pattern. Rodents (mice, rats, guinea pigs) are the most 
common species used in research accounting for over 50% of studies (Clancy et al., 
2007), and are the choice of animal for the current proposal. This proposal uses a rodent 
model of ethanol exposure because of the similarities between human and rodent CNS 
development (Dobbing & Sands 1979). Dose is also a very important consideration when 
modeling ETOH exposure; the quantity used in an animal model is extremely important 
in determining whether you are trying to model more or less severe ethanol effects.  A 
wide range of blood alcohol levels have been used ranging from 100-400mg/dl; this 
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equates roughly to moderate to heavy binge-like ethanol exposure (Patten, 2014). The 
route of administration is also important when considering an animal model because of 
the various benefits and drawbacks. The most commonly used in modeling fetal ethanol 
exposure includes voluntary drinking and intubation method (Patten, 2014). Both of these 




 trimester) and 
neonates (modeling 3
rd
 trimester) (Patten, 2014). Intubation is more typically used for 
controlled dosing, because voluntary consumption is highly subject to individual 
differences. However, both higher and more moderate BACs resulting from these routes 
of administration are correlated to increased neurotoxicity and decreased white matter in 
a dose-dependent fashion (Patten, 2014).   
The developing mammalian nervous system is particularly sensitive to the effects 
of teratogenic compounds. During development, the burgeoning nervous system goes 
through massive amounts of cell generation, migration and proliferation, and finally 
pruning and cell death, processes which occur throughout life but at a slower pace (de 
Graaf-Peters & Hadders-Algra, 2006; Patten et al., 2014). This process occurs at different 
rates and times during gestation, with some regions going through rapid changes later in 
development. Uniquely, small animals such as rodents go through this development at 
different times than do humans. In humans, gestation occurs over three characteristic 
trimesters (3, 3-month blocks) all of which occur prenatally.  During these trimesters the 
brain is going through rapid development, with the first two trimesters characterized by 
the formation of the neural tube, gastrulation, some cell proliferation and migration. The 
third trimester in humans is commonly referred to as the “brain growth spurt,” and is a 
time where the brain is undergoing rapid growth (Dobbing & Sands 1979). In rodents, 
gestation typically occurs within 18-23 days compared to around 280 days in humans. 
Extensive research investigating the differences between human and animal CNS 
development has produced maps known as  “trimester equivalents” in rodents using 
anatomical comparisons and differences in cellular number (both glial and neural) to 
compare the development of the two species. The first trimester equivalent in rodents is 
roughly during gestational days (GD) 1-10, with GD 10-20 roughly corresponding to the 
2
nd
 trimester, and the third trimester mostly occurring after birth during post natal days 
(PND) 1-10 (Clancy et al., 2007). However, these times are not concrete and represent a 
8 
 
loosely organized trajectory that has considerable overlap throughout development. 
Utilization of this information has informed researchers in producing models of diseases 
and disorders that occur during these times. Investigating the effect of ethanol on the 
developing fetus has produced several ethanol exposure methods that utilize either a 
prenatal (exposure during gestation) or neonatal (exposure shortly after birth) paradigm 
(Berman & Hannigan 2000). In the prenatal exposure paradigm, the pregnant dam is 
exposed to ethanol either through diet or by intragastric intubation (Berman & Hannigan, 
2000; Kelly & Streissguth 2000; Thomas et al., 2009). Prenatal exposure to ethanol has 
been shown to lead to deficits in social behavior (e.g. play behavior, social recognition, 
and active interaction), activity (hyperactivity and impulse control), and 
learning/memory, which is associated with deficits found in FAS/FASDs in humans 
(Berman & Hannigan 2000; Driscoll et al., 1990;  Kelly & Steissguth, 2000).  Other 
behavioral characteristics associated with prenatal ethanol exposure include feeding 
difficulties, low birth and brain weight, poor reflex development and motor function, and 
increased activity. All of these have correlates with clinical populations of children with 
FAS (Driscoll et al., 1990; Thomas et al., 2009).  
 Another model is used to focus more specifically on the effects of “3
rd
 trimester” 
exposure, in which rat pups are exposed to ethanol during the first weeks of postnatal life 
(Goodlett & Johnson 1997; Goodlett & Peterson 1995; Kelly & Tran 1997; Riley et al., 
1993; Wellmann et al., 2010). With this model, the offspring receives ethanol either 
through a temporary or indwelling intragastric feeding tube.  For the model using oral 
intubation the dose of ethanol typically ranges between 2 and 6 grams per kilogram 
(g/kg) of ethanol a day, with higher doses (6 g/kg) producing BACs of more than 200 
milligrams per deciliter (mg/dl) (Patten et al., 2014). An advantage of this model and 
other intubation models is the relative ease with which the experimenter can control the 
dose of ethanol received, resulting in fairly predictable BACs. Also, intragastric 
intubations do not require surgical implantation of feeding tubes. Previous research has 
shown that ETOH exposure using this method produces deficits in a variety of behavioral 
paradigms that assess motor coordination (Idrus et al., 2011; Lewis et al., 2007; Thomas 
et al., 2004), activity (Smith et al., 2012; Thomas et al., 2007), and learning and memory 
(Hunt et al., 2009; Thomas et al., 2009; Tiwari et al., 2012). This evidence has helped 
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demonstrate the validity of the model because the deficits found closely parallel the 
deficits commonly seen in clinical populations of FASDs (Kelly et al., 2000; Lewis et al., 
2007; Riley et al., 1993; Thomas et al., 2004; Tran et al., 2000; Wellman, 2010).  
Summary: 
 The development of FAS/FASDs through the exposure to ethanol during prenatal 
development remains an important social and clinical problem.  There is no simple 
solution for this disorder because of the various constraints discussed above and the 
complicated nature of the disorder itself. As a result, research continues in the 
development of better understanding some of the mechanisms that underlie the 
development and consequences of FAS. This basic research is essential and may provide 
potential relief for a disorder that currently has no clear solutions.  
A Possible Treatment 
Treating FAS 
Currently, there are no effective clinically-approved pharmacotherapies for the 
treatment of toxicity induced by ethanol withdrawal in the fetus or newborns that were 
exposed to ethanol during pregnancy.  Therefore, it is clear that development of 
pharmacotherapies aimed at reducing the damage caused by ETOH exposure are needed. 
One type of pharmacotherapy for FAS/FASDs can either focus on reversal/prevention, 
such that treatment is administered during gestation or shortly after birth when the 
diagnosis of the disorder has not yet occurred (Riley et al., 2011). Classically, therapies 
aimed at treating children with FAS/FASDs have been focused on providing supportive 
and protective environments for optimal outcomes (Pruett et al., 2013). Medication for 
the management of these cognitive symptoms are most often the same drugs used for the 
management of disorders like ADHD, a comorbid diagnosis commonly made in children 
with an FASD (Pruett et al., 2013). This treatment strategy has had mixed results in 
children with FASDs where symptoms of inattention were not reduced (Doig et al., 
2007). Another study looking at a variety of treatments found that various medications - 
whether they are stimulants, SSRIs, or mood stabilizers - have some degree of success in 
patients with FAS, but no single medication could treat all the symptoms associated with 
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the disorder (Coe et al., 2001). Previous cellular and behavioral work in animals has 
outlined the importance of ethanol withdrawal after exposure as being a potentially 
treatable source of cellular toxicity related to FAS/FASDs.  Neonates exposed to chronic 
levels of ETOH often experience many periods of withdrawal during and after birth 
because of binge-like exposure to ETOH during gestation. Withdrawal from ethanol in 
the neonate is severely damaging to the CNS and produces many deficits demonstrated 
both in cellular (de Fiebre et al., 2003; Li et al., 2004; Prendergast et al., 2000 & 2004) 
and in-vivo models (Barron et al., 2008; Goodlett & Horn 2001; Thomas et al., 1997 a. 
and b.). The development of a pharmacotherapy aimed at reducing the damage associated 
with this ethanol withdrawal (EWD) is appealing because it is potentially a one-time 
treatment that would protect the fetus or newborn after ethanol has left the system, either 
during parturition or when a mother is seeking help for a use disorder. Most research has 
focused on targets that are involved directly with the damaging effects of ethanol, and 
because ethanol’s effects on the developing CNS are numerous, many compounds have 
been studied for their potentially therapeutic effect. A few examples of compounds used 
prenatally to treat the teratogenic effects of ethanol follow. Using in-vitro models, 
researchers have examined ethanol’s ability to inhibit L1, an immunoglobulin responsible 
for cell adhesion and neuronal migration. It is thought that if ethanol’s action on L1 could 
be reversed pharmacologically that it would reduce ethanol’s damaging effects on the 
fetus (Wilkemeyer et al., 2000).  Other compounds like ascorbic acid (vitamin C) have 
also been investigated in Xenopus embryos and was able reduce damage produced by 
reactive oxygen species produced by chronic ethanol exposure (Peng et al., 2005). Other 
compounds like buspirone and ipsapirone, both serotonergic agonists, have also been 
used to prevent ethanol damage to serotonergic neurons during pregnancy (Pruett et al., 
2013). There is also much work focusing on reducing cell damage via the glutamatergic 
system via direct action or modulation at the n-methyl-d-aspartate (NMDA) receptor. For 
example, CP-101-606 (a novel NR2B NMDA receptor antagonist) and MK-801 (a 
noncompetitive antagonist) were able to attenuate behavioral deficits caused by ethanol 
exposure (Lewis et al., 2011; Thomas et al., 1997). Although much of the work using 
various compounds that utilize different neuronal systems have had varying degrees of 
success in reducing behavioral deficits and cellular damage related to ethanol exposure, 
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none of them have yet been approved for clinical treatment of this problem. Because of 
this, research continues in searching for compounds that have potential in treating ethanol 
withdrawal-related toxicity.   
A Promising Candidate  
The Cholinergic System  
 Because no clinically-approved pharmacotherapy currently exists to 
treat/reduce/reverse the damage caused by ethanol/EWD, much research has been 
conducted on various drugs that have been shown to have neuroprotective properties (as 
described above). One promising avenue is using drugs that target cholinergic receptors, 
which is the focus of this proposal.   
The cholinergic system is one of the most widespread and commonly studied 
systems in the nervous system. Its functions are varied by region, and span both the 
central and peripheral nervous systems. In the CNS, the cholinergic system is thought to 
be a facilitator of processes related to wakefulness and attention, and is thought to play a 
critical role in both learning and memory (Thomas, 2003).  Ethanol’s effects on the 
cholinergic system are widespread, with exposure to high doses of ethanol during the 2
nd
 
week of gestation producing a loss of immunoreactivity to choline-acetyltransferase 
(ChAT, an enzyme that signals the presence of acetylcholine-containing cells) in the 
medial septal nuclei, caudate, and putamen, but not a loss in the number of cells present 
(Heaton et al., 1996; Nagahara & Handa 1999 a.). These results suggest that cholinergic 
function was impaired in the first weeks of prenatal development, but research looking 
further into development showed that eventually these deficits decreased and returned to 
control levels (Nagahara & Handa 1999 a.). Also, physostigmine, an acetylcholinesterase 
inhibitor that increases the amount of available ACh (acetylcholine), reduced 
hyperactivity in rats following prenatal ETOH compared to controls (Nagahara & Handa 
1999 b.). In addition, when exposed to ethanol during the last two weeks of gestation, 
nicotine did not produce the typical alterations in locomotor behavior or an increase in 
memory performance when compared to control animals (Nagahara & Handa 1999 b.). 
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 Ethanol is also thought to affect both cholinergic receptor systems (muscarinic 
and nicotinic) within the developing CNS.  For the muscarinic system, studies have found 
that during postnatal development there is an up-regulation of muscarinic ACh receptors 
in the hippocampal formation in response to ethanol exposure (Nio et al., 1991). Also in 
these same studies, scopolamine (a muscarinic antagonist) impaired fetal ETOH-exposed 
rats in an alternation based task.  Finally, when exposed to ethanol during early postnatal 
development, PND 4 and 8 (via intragastric intubation), rats showed an increase in 
striatal muscarinic receptor affinity (Light et al., 1989). Sex differences were again 
observed; ETOH-exposed female rats had fewer cholinergic receptors in the striatum and 
cerebellum (Light et al., 1989). This evidence suggests that exposure to ethanol during 
development alters the function of the muscarinic cholinergic system and may affect 
males and females differently.  
The Nicotinic Receptor System 
 The nicotinic receptor system is a component of the cholinergic system and plays 
many crucial roles in both the peripheral and central nervous systems. The receptor is 
named so because of its high affinity for nicotine (a psychoactive chemical commonly 
found in tobacco). These receptors were the first membrane receptor proteins identified in 
the 1970s (Dani, 2001). They fall into a class of ligand-gated ion channels that respond 
endogenously to acetylcholine or exogenously to nicotine (Dani, 2001; Pauly et al., 
2004). The function and location of the receptor in either the CNS or peripheral nervous 
system (PNS) is dependent upon the type and arrangement of its subunits.  The nicotinic 
receptor is an ion-channel that is made of five membrane-spanning regions; each of the 
five constituent regions is composed of different or similar subunits (Wu & Lukas, 2011). 
The subunits that form nicotinic receptors in neural tissue include alpha (2-9) and beta (2-
4); these subunits can be arranged in many different conformations that are either 
heteromeric (alpha2-alpha6 and beta2-beta4), or homomeric (alpha7-alpha9) (Dani, 
2001).  
 Deficits in nicotinic receptors have been implicated in several neurological 
disorders including Alzheimer’s disease, Parkinson’s diseases, and Down’s syndrome 
(Levin, 2002). Along these lines, agonists targeting the nicotinic receptor system have 
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been shown to be neuroprotective. Pre-treatment with nicotine, carbachol (mixed 
nicotinic/muscarinic agonist), and nornicotine has been shown to be neuroprotective 
against the excitotoxic effects of excessive glutamatergic activity in cortical cell cultures 
(Ferchmin et al., 2003; Marin et al., 1994; Akaike et al., 1994). Nicotine treatment can 
also reduce cellular toxicity induced by ischemic damage both in-vivo and in-vitro in 
gerbils and rats (Pauly et al., 2004). Nicotine can also reduce the damage caused by beta-
amyloid plaques, related to the development of Alzheimer’s disease (Shimohama et al., 
2001).  
 In the nicotinic system, evidence for the role of cholinergic systems in the effects 
of ethanol exposure stems from research using choline supplementation, an essential 
nutrient used in the production of acetylcholine that is also thought to activate nicotinic 
receptors. Perinatal choline supplementation been shown to reduce open field 
hyperactivity, spatial working memory deficits, eyeblink and trace fear conditioning 
deficits (Monk, 2012). Thomas and colleagues (2009) have also found that choline 
supplementation in early development can lessen the severity of reduced birth and brain 
weight after ethanol exposure (Thomas, 2009). Choline’s effect on cholinergic 
functioning in a model of ethanol exposure is thought to be mediated in part by the 
nicotinic receptor system, of which choline has been shown to be a direct agonist 
(Coutcher, 1992; Thomas, 2013). In animal models, nicotine exposure can reduce deficits 
related to learning and memory as well as an ability to increase cell survival after hypoxic 
events, brain damage, and excitotoxicity (Hejmadi et al., 2003; Miwa et al., 2011; Levin 
& Rezvani, 2000;  Lloyd, G. 2000;  Pauly et al., 2004; Prendergast et al., 2001a & b). 
Research has also shown that nicotine treatment during ethanol administration can reduce 
cell death produced by ethanol-related toxicity in cultured granule cells of the cerebellum 
(Tizabi et al., 2003). However, nicotine is relatively non-specific for various nicotinic 
receptor subtypes causing activation of both central and peripheral cholinergic systems. 
This decreases the usefulness of a nicotine-like drug aimed at treating humans. In order to 
avoid problems associated with the activation of peripheral targets and find a drug that 
specifically and exclusively activated neuronal nicotinic receptors, other compounds need 
to be explored.   
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Alpha-7 Nicotinic Acetylcholine Receptor 
Of the nicotinic receptors implicated in nicotine’s neuroprotective effects, the 
alpha 7 nicotinic acetylcholine receptor (α-7 nAChR)  is of particular interest because of 
its high concentration in neuronal tissue throughout the CNS (Dani, 2001).  Stimulation 
of the α-7 nAChR has increased cognition and decreased behavioral deficits in animals 
(Timmermann et al., 2007; Olincy et al., 2007). This receptor has also been implicated in 
mediating synaptic plasticity and regulation of immune function (Kem, W. 2000). 
Activation of the receptor can result in a reduction in cellular toxicity from ethanol 
withdrawal (de Fiebre et al., 2003 & 2005; Yangxin et al., 2002), neuroinflammation 
(Concepcion et al., 2008; de Jonge et al., 2007), glutamatergic toxicity (Dajas-Bailador et 
al., 2000 & Shimohama et al., 1998), and  traumatic brain injury (Pauly et al., 2004) .  
α-7 nicotinic receptors are some of the most heavily expressed nicotinic receptors 
in the CNS, and to a lesser extent in the immune system (Dani, 2001).  High densities of 
this receptor are found in the hippocampus, cerebellum, prefrontal cortex, motor cortex, 
and basal ganglia (Dani, 2001; Concepcion et al., 2008). The expression of the α-7 
nAChR is first observed on neuroblasts early in gestation (Miwa et al., 2011).  Also, 
receptor expression steadily increases until birth. In the third trimester, the density of α-7 
receptors in the hippocampus is roughly 3x that of an adult (Miwa et al., 2011). The 
receptor responds endogenously to several compounds; in adults this is more commonly 
ACh, but in the neonate it is postulated that choline is the primary endogenous compound 
acting at the receptor (Miwa et al., 2011). Choline, which has a greater presence in 
neonates than adults, has roughly 3x the affinity on the α-7 than does ACh (Miwa et al., 
2011). Activation of hippocampal α7 nAChRs has led to decreases in learning and 
memory deficits commonly associated with diseases like Alzheimer’s (Meyer et al., 
1998; Timmermann et al., 2007). In neurons, these receptors are located on the cell at the 
axon terminal, the pre-terminal (region just before the terminal that can affect several 
terminals at once), postsynaptic dendritic membrane, and on glial cells (Albuquerque et 
al., 2009). The α7 nAChR is selectively permeable to calcium, and is responsible for fast 
postsynaptic transmission, the modulation of release of numerous transmitters, and long-
term potentiation in various areas throughout the brain (Hurst et al., 2013; Dani, 2001; 
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Fabian-Fine et al., 2001). Its permeability to calcium is unique in that the receptor does 
not require depolarization of the neuron to open (Timmermann et al., 2007). Activation of 
alpha-7 nAChRs produces a modulatory action which stimulates the release of several 
neurotransmitters (Timmermann et al., 2007). The α-7 nAChR plays many roles in 
modulating processes in the brain both pre- and postsynaptically. Postsynaptically, α-7 
nAChRs are found on inhibitory GABA’ergic interneurons throughout the hippocampus 
and receive input from the medial septal nuclei, which plays a role in sensory response 
within this structure (Miwa et al., 2011). This modulation of inhibitory GABA’ergic 
interneurons causes the decrease of glutamatergic response in the pyramidal cells of the 
hippocampus (Miwa et al., 2011). Choline administration during late gestation, during 
peak α-7 nAChR density, can decrease the number of these receptors and increase 
excitability and dendritic development in the hippocampus (Miwa et al., 2011). However, 
choline deficiency, a common occurrence during gestation, is thought to be damaging to 
the developing CNS. Choline supplementation has been shown to be neuroprotective in 
several paradigms, including animal models of FAS/FASDs (Miwa et al., 2011; Pauly et 
al., 2004; Thomas et al., 2004, 2007 & 2009). Also, in late prenatal to early postnatal 
development, the α-7 nAChR is responsible for the transformation of glutamate 
neurotransmission from primarily NMDA-type to kainate-aspartate receptors (Miwa et 
al., 2011).  These actions could be important in the α-7 nAChR’s effects in mediating the 
excitotoxic response to ethanol withdrawal. Because ethanol withdrawal is commonly 
associated with increased activity of glutamatergic receptors that can lead to excitotoxic 
death, it seems contradictory that possibly stimulating its release through α-7 agonism 
would decrease excitotoxicity.  Several mechanisms could be at work to reduce EWD-
induced toxicity. One of the most commonly postulated mechanisms of action for the α-7 
nicotinic receptors’ effects on ethanol neurotoxicity is the ability of the receptor to reduce 
calcium toxicity, caused by activation of the NMDA receptor during ethanol withdrawal 
(de Feibre et al., 2003; Shimohama et al., 1998).  For  review on NMDA-induced toxicity 
during ethanol withdrawal (see Tsai et al., 1998; Kalluri et al., 1998; Grant et al., 1990; 
Eckardt et al., 2006; or Prendergast et al., 2001a. and b.). Nicotine administration during 
ETOH withdrawal (EWD) has been shown to decrease this calcium-induced 
excitotoxicity through several possible metabolic mechanisms including the buffering of 
16 
 
internal calcium stores due to calbindin D28K (a calcium sequestering protein) during 
early development (Prendergast et al., 2001 a.). Prendergast and colleagues (2001 a.) also 
believe that activation of the α-7 nicotinic receptor could possibly be down-regulating the 
expression of the NMDA receptor and decreasing withdrawal-induced toxicity 
Administration of the nicotinic antagonists alpha-bungarotoxin (BTX) or 
methyllycaconatine (MLA), which block the α-7 nAChR, negates nicotine’s protective 
effects in NMDA-induced toxicity supporting the role of α-7 receptors in neuroprotection 
(Ferchmin et al., 2003). Another mechanism postulated to lessen EWD-induced toxicity 
is to reduce the release of reactive oxygen species and cytochrome C (a signal for 
apoptosis) from the mitochondria (also the primary store for intracellular calcium) caused 
by α-7 nAChR activation (Li et al., 2000 & 2002). This process is thought to be 
modulated by the activation of protein kinase C (PKC), which can reduce the release of 
cytochrome C (Li et al., 2002). Further support for α-7 nAChR’s role in reduction of 
toxicity induced by EWD stems from data showing that α-7 nAChR knockout (KO) mice 
do not display nicotine-induced neuroprotection (Gahring et al., 2003).  
DMXB-A  
DMXB-A is a derivative of an anabaseine compound found in marine worms 
(Olincy & Stevens, 2007). It has a high affinity for the α-7 nAChR, showing about 40% 
of the efficacy of ACh for the receptor and a much lower affinity for other nicotinic 
receptors like the α4β2 and type 3 5-HT receptors where it acts as an antagonist (Kem et 
al., 2006; de Feibre, 2003; Olincy & Stevens 2007).  Studies have shown that DMXB-A 
may act as a noncompetitive partial-agonist with higher doses desensitizing the receptor 
and lower doses activating them (Kem et al., 2006). It is a lipophilic compound that 
readily crosses lipid membranes such as the blood brain barrier (BBB) easily (Kem et al., 
2006). In the human brain, DMXB-A is less potent than nicotine (Ki=2000) when 
displacing α-BTX, however in the rat brain DMXB-A is more potent than nicotine at 
displacing α-BTX at the α-7 nAChR (Ki=650) (Briggs et al., 1997).    
Many studies looking at α-7 nAChR’s protective properties have used 3-
dimethoxybenzylidene-anabasine (DMXB-A) or otherwise known as GTS-21.  The drug 
was the first α-7 nAChR agonist to be used in clinical testing for the treatment of 
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schizophrenia, Parkinson’s disease, and Alzheimer’s disease (AD) (Freedman et al., 
2014; Kem et al., 2006; Meyer et al., 1997). In phase II clinical studies of patients with 
schizophrenia, DMXB-A improved attention and memory and sensory inhibition in an 
animal model of schizophrenia (Freedman et al., 2014; Olincy et al., 2007). DMXB-A 
was neuroprotective against beta-amyloid toxicity in an animal model of AD (Kem, 
2000; Kihara et al., 1997). DMXB-A also improves cognitive function following 
administration of beta-amyloid (Chen et al., 2010; Meyer et al., 1997). DMXB-A has also 
shown to be neuroprotective in animal models of global ischemia (Nanri et al., 1998). 
Data from in-vitro studies also suggest that DMXB-A can dose-dependently reduce cell 
death following ETOH exposure (de Fiebre et al., 2003; Li et al., 2000 & 2002; 
Shimohama et al., 1997). Using an embryonic primary hippocampal cell culture model to 
study the effects of DMXB on ethanol toxicity, De Fiebre and colleagues (2003) found 
that DMXB effectively increased cell viability after ethanol administration. Also, pre-
treatment with DMXB-A at low doses increases cell survival during an ethanol challenge 
(Li et al., 1999). Most previous studies either used a pre-treatment or a concomitant 
method for administering DMXB-A with ethanol, but no previous research using a third-
trimester chronic ethanol model with post-ethanol exposure of DMXB-A has been 
examined. Thus, further investigation into the therapeutic potential for DMXB-A is 
warranted.  
The exact mechanism with which activation of the α-7 nAChR works to reduce 
the toxic effects of ethanol exposure and withdrawal remain somewhat unclear. However, 
as mentioned above, this process is most likely mediated by several different mechanisms 
that work in unison to reduce toxicity. Studies that have explored the interaction between 
DMXB-A and ethanol-induced toxicity have shown that the drug prevents ethanol-
induced increases in intracellular calcium, the buildup of reactive oxygen species, and the 
release of cytochrome C (Li et al., 2000). Other studies have suggested that the protective 
effects of DMXB-A might not be due solely to the activation of the α-7 receptor, but due 
to action on other nicotinic receptor subtypes as well (de Feibre et al., 2003).  Another 
emerging hypothesis using a neuro-inflammation model, indicates the actions of α-7s 
expressed on microglia and possibly macrophages could contribute to the neuroprotection 
in models of cellular stress (Parada et al., 2013). However, no research, to the best of my 
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knowledge, has examined the effects of DMXB-A on “third trimester” ETOH exposure 






















 Chapter 2: 
Testing DMXB-A’s Effects in an Organotypic Hippocampal Slice Culture Model 
Hypothesis   
 The current hypothesis is that the α-7 nAChR agonist DMXB- A should reduce 
the amount of cell damage caused by chronic ethanol exposure and withdrawal in a 
developmental organotypic hippocampal slice culture in a rodent model. Investigation 
into this is of importance in furthering the understanding of the potential therapeutic 
efficacy of α-7 agonists on the development of FAS/FASDs.  
Methods: 
Organotypic Hippocampal Slice Culture: Overview 
The organotypic hippocampal slice culture (OHSC) model was developed in 1981 
by Gahwiler and colleagues (Gahwiler, 1981) and simplified by Stoppini and colleagues 
in 1991 (Stoppini et al., 1991). OHSC has since been used as an investigative tool to 
study both pharmacological and environmental manipulations that could provide 
neuroprotection, neurogenesis, and/or neurotoxicity.  The OHSC model has many 
benefits relative to simpler in-vitro culture models (like primary cell culture models) that 
make it a useful model to use when investigating neurotoxicity. First, it allows for the 
maintenance of neurons and glia and maintains much of the complex circuitry of an intact 
hippocampus (Noraberg et al., 2005), providing a more valid model in assessing 
neuroprotection and neurorepair and allowing easy quantification of cell markers, 
including cell damage. This model also allows investigators to characterize compounds of 
interest, possibly revealing their mechanism of action. Through much investigation 
OHSC has shown sensitivity to a variety of insults including ETOH; for review see 
(Noraberg et al., 2005). 
Hippocampal slice culture models are particularly useful for studying excitotoxic 
damage related to chronic ethanol exposure in the current study because of the 
susceptibility of the hippocampus to toxicity related to ethanol withdrawal. As stated 
previously, the hippocampus is also useful in a culture model using DMXB-A because of 
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the high concentration of α-7 nAChRs which have been implicated in EWD-related 
neuroprotection in this structure.  Also, the hippocampus is heavily implicated in some of 
the cognitive and behavioral deficits observed following fetal alcohol exposure, such as 
impaired learning and memory.  
Animals 
Male and female Sprague-Dawley rat pups were used for this experiment. The 
animals were obtained through breeding in the rat vivarium in Kastle Hall. All animals 
were housed in a 12 hour light/dark cycle, and were allowed continuous access to food 
and water. After each breeding session pregnant females were identified by the presence 
of a vaginal plug. Pregnant females were removed from the colony and taken to a 
temperature and humidity controlled nursery for the duration of their pregnancy. After 
parturition, pups remained with their mother until postnatal day (PND) 1. On PND 1, 
litters were culled to 10, maintaining 5 male and 5 female pups when possible; allowing 
for an even distribution of subjects between the experimental groups and sexes.  The care 
of animals was carried out in accordance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996), as 
well as the University of Kentucky’s Institutional Animal Care and Use Committee 
Hippocampal Slice Culture Preparation and Treatments 
On PND8, non-treated litters were sacrificed for brain removal. The brains were 
removed and placed in a tissue culture dish containing dissecting medium [Minimum 
Essential Medium (Gibco BRL, Gaithersburg, MD), 25 mM HEPES (ATCC, Manassas, 
VA), 200 mM L-glutamine (Invitrogen, Carlsbad, CA), 50 μM streptomycin/penicillin 
(ATCC, Manassas, VA)].  The hippocampus from each brain was removed and then 
sliced coronally at 200 um using a McIllwain Tissue Chopper (Campden Instruments 
Ltd., Lafayette, ID). Slices were separated and placed on Teflon membrane inserts 
(Millicell-CM 0.4 μm; Millipore, Marlborough, MA, USA). Each insert holds 3 slices 
with 6 inserts per culture plate. The wells contained 1mL culture media [dissecting 
media, 36 mM glucose, 25% Hanks’ balanced salt solution (HBSS; Gibco BRL, 
Gaithersburg, MD), 25% heat-inactivated horse serum (HIHS; Sigma, St. Louis, MO)]. 
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Plates were then placed in an incubator (37°C/5%CO2/95%air) for 5 days in vitro (DIV) 
for adherence to the Teflon membrane. 
On DIV 5, the inserts were split into a 100mM ETOH-treated and control groups. 
After the groups were divided, the 6 well plates were placed into propylene containers 
with 50mL of control or 100 mM ETOH (averaging approx. 65mM over 5 days in vitro 
[Prendergast et al. 2004]) in sterile water with 50uM gentamicin added to avoid chances 
of bacterial growth. The plates were placed into plastic freezer bags and inflated with an 
air mixture to prevent ETOH evaporation. This procedure was repeated on DIV 10 to 
provide the slices with fresh ETOH.  On DIV 15 the slices were removed from control or 
ETOH media and treated with a combination of DMXB-A (at 0, 1, 3 or 10uM) control 
media, and/or NMDA (5um), giving a total of 16 treatment groups (Table 1.). During the 
24-hour treatment period, slices were also exposed to the fluorescent marker propidium 
iodide (PI; 3.74 μM, SigmaAldrich). PI is an indicator of cellular damage because it binds 
to the DNA of cells whose membranes have been compromised (in this case by EWD-
induced toxicity) and produces red fluoresces when exposed to 488nm waves of light. 
Twenty-two hours later, slices were imaged using fluorescent microscopy. The images 
were captured using SPOT Advanced version 4.0.9 software for Windows (W. 
Nuhsbaum Inc., McHenry, IL, USA) using a 5X objective connected to an inverted Leica 
DMIRB microscope (W. Nuhsbaum Inc.) fitted for fluorescence detection (mercury-arc 
lamp) and connected to a computer via a SPOT 7.2 color mosaic camera (W. Nuhsbaum 
Inc.).  PI uptake in the CA1, CA3, and DG cell layers were measured using ImageJ 
version 1.46 software (National Institute of Health).  Raw fluorescent values were 





Table 1.  
Treatment Groups: 2 control groups, 2 NMDA groups, 6 DMXB groups, 6 
NMDA+DMXB groups. 
Power Analysis  
Before beginning the study, an apriori analysis was run to determine the number 
of culture preparations needed to achieve 90% power when detecting a medium-sized 
effect (f= .25) in a study using 16 groups. This required a minimum of 6 culture 
preparations at roughly 144 slices per prep.  
Statistical Analysis 
 Analyses were conducted using IBM Statistical Package for the Social Sciences 
(SPSS) version 22 software (IBM Corporation, 2014). First, the three regions of the 
hippocampus were analyzed together to determine if there were differences in treatment 
groups between the regions. After this, each hippocampal region was investigated using a 
2-way (sex x group) univariate general linear model (GLM) analysis of variance 
(ANOVA) to explore variance in and among the factors. Each culture replication was 
also used as a covariate during initial analysis to assess the effect of litter on the 
individual repetitions of each culture preparation.  If significant interactions were 
detected, further investigation using a post hoc pair-wise comparison with Tukey’s 
DIV 15 
0 DMXB (+/- 5µM 
NMDA) 
1µM DMXB (+/- 
5µM NMDA) 
3µM DMXB (+/- 
5µM NMDA) 
10µM DMXB (+/- 
5µM NMDA) 
DIV 5-15 





correction for family-wise error was used. For simple graphical representation, mean 
levels of toxicity for each group were converted to percent control.  
Results 
 To investigate whether there were group differences between the three regions of 
the hippocampus (CA1, DG, and CA3), an ANOVA was run with region as a repeated 
measure. The ANOVA was a 2 (sex) x 3 (region) x 16 (treatment) design.  
Analysis revealed that there was that there was a main effect of treatment between 
the three regions, where F(1, 15)=11.805 ,p<.001, and sex F(1,15)=9.753, p<.005, with a 
non-significant interaction between the two of F(1,15)=1.420, p=.130. Because of 
previous research in this lab and others using an OHSC model of EWD supporting 
variations in outcome between the three regions (specifically the CA1), an a-priori 
hypothesis warranted the investigation of the individual regions separately.  
CA1 
In the CA1, using a 2-way ANOVA (treatment x sex), there was a main effect of 
treatment F(15,31)=10.851, p<.001 and an interaction between treatment and sex 
F(15,31)=1.811, p<.05. Because of this interaction between treatment and sex in the 
CA1, further analyses in this region were completed separately by sex. For both males 
and females there was a main effect of treatment F(15,15)=6.752, p<.001, and 
F(15,15)=5.954, p<.001 respectively. Because of this, a Tukey’s correction for family-
wise error post hoc test was utilized to explore these group differences. Significance was 
set at p<.05. 
 In slices exposed to ETOH + NMDA that were treated with 1, 3, and 10um of 
DMXB-A, there was a significant reduction in fluorescence (p<.005 for females at all 
three doses, and p<.05 for males at all three doses) compared to ETOH + NMDA alone 
(fig.1). Female slices treated with ETOH+NMDA alone showed greater fluorescence 
when compared to controls than did male slices (197% vs 163% fluorescence of control, 
respectively) (fig.1).  
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 Differences between males and females also persisted with exposure to NMDA.  
Male slices exposed to NMDA alone expressed greater fluorescence compared to control 
slices (188% of control, p<.001) than did female slices (141% of control, p<.05) (fig.2). 
In males, increasing the dose of DMXB-A reduced PI fluorescence, and at 3 and 10 μm 
DMXB-A, this difference was significant (p<.05 for both doses) (fig.2). However, in 
females, when treated with 1μm DMXB-A, fluorescence significantly increased 
compared to NMDA alone (p<.005) (fig.2). This increase in fluorescence was reduced to 
near control levels in females treated with 10 μm DMXB-A.  
 When treated with ETOH (fig. 3), slices were not significantly different between 
males and females. Fluorescence in slices treated with ETOH alone was comparable to 
control slices. However, when treated with 3 and 10 μm DMXB-A, both male and 
females slices had increased fluorescence compared to controls; this difference was 
significant for males at 3μm DMXB-A (p<.05) and for females at 10μm DMXB-A 
(p<.05).   
 In control slices, for both sexes, treatment with 1μm DMXB-A produced levels of 
fluorescence comparable to controls (fig.3). However, treatment with 3μm of DMXB-A 
produced a significant increase in PI fluorescence compared to controls (females 
[p<.005], males [p<.05])(fig.3).  However, only in males did treatment with 10μm 
DMXB-A produce significantly increased fluorescence when compared to controls 
(p<.001) (fig.4). 
CA3 & DG:  
 In both regions there was a main effect of treatment, F(15,31)=14.767, p<.001 for 
the CA3 and F(15,31)=15.330, p<.001 for the DG. Unlike the CA1, there was no effect of 
sex and no interaction between treatment and sex.  To investigate individual group 
differences a Tukey’s correction for family-wise error post-hoc test was utilized, and 
significance was set at p<.05. 
In the CA1, fluorescence in control slices for both the DG and CA3 when treated 
with 1, 3, and 10 μm DMXB-A was significantly increased when compared to controls 
(p<.05 or greater for all three doses in both regions) (fig.5). This increase in fluorescence 
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was closer to control levels only in slices treated with 1μm DMXB-A (around 117% 
fluorescence of control) (fig. 5).  
In slices exposed to ETOH, treatment with 3 and 10 μm DMXB-A significantly 
increased fluorescence when compared to controls in both regions (p<.05) (fig. 6). This 
increase was not present in ETOH slices treated with 1μm DMXB-A for either region. In 
Slices exposed to NMDA, for both regions, there was a significant increase in 
fluorescence compared to controls (p<.05) (fig. 7). This also occurred in NMDA exposed 
slices when treated with 1 and 10μm DMXB-A. However, this increase in fluorescence 
was not found in NMDA slices treated with 3μm DMXB-A (fig. 7). Finally, in slices 
exposed to both ETOH and NMDA, for both regions, there was no difference in 
fluorescence when compared to controls (fig. 8). These results persisted with all three 


















































Fig 1.  PI uptake expressed as percent control in the CA1 region of the hippocampus, in 
slices exposed to ETOH+NMDA 24 hours after ethanol withdrawal, treated with four 
levels of DMXB-A (0, 1, 3, and 10 μm). ETOH/NMDA slices treated with 1, 3, and 10 
μm DMXB-A had significantly reduced PI expression compared to ETOH/NMDA slices. 




































Fig 2. PI uptake expressed as percent control in the CA1, in slices exposed to NMDA, 
treated with four levels of DMXB-A (0, 1, 3, and 10 μm). Male slices exposed to NMDA 
alone expressed greater fluorescence compared to control than did female slices (188% vs 
141% of control, respectively), but when treated with 1μm DMXB-A, fluorescence in 
females slices exposed to NMDA was greater than males (203% vs. 158% of control, 



































Fig. 3: PI uptake expressed as percent control in the CA1, in slices exposed to ETOH, 
then treated with four levels of DMXB-A (0, 1, 3, and 10 μm). ETOH exposure alone did 
not increase fluorescence compared to controls. 3 and 10 μm DMXB-A increased 
fluorescence in slices treated with ETOH in both sexes. When treated with 1 μm DMXB-




































Fig 4.  PI uptake expressed as percent control in the CA1, in control slices, treated with 
four levels of DMXB-A (0, 1, 3, and 10 μm). DMXB-A increased fluorescence with all 
three levels of DMXB-A in both sexes. Slices treated with 1μm DMXB-A, however, did 







































Fig. 5: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in control 
slices treated with four levels of DMXB-A (0, 1, 3, and 10 μm). For both regions, 
treatment with DMXB-A significantly increase fluorescence compared to control slices. 
However, 1μm DMXB-A reduced this fluorescence compared to both 3 and 10 μm 




































Fig. 6: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in ETOH 
slices during EWD, treated with four levels of DMXB-A (0, 1, 3, and 10 μm). For both 
regions, treatment with 3 and 10 μm DMXB-A significantly increase fluorescence 
compared to control slices. However, 1μm reduced this fluorescence compared both 3 










































Fig. 7: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in NMDA 
exposed slices, treated with four levels of DMXB-A (0, 1, 3, and 10 μm). NMDA alone 
significantly increased fluorescence for both regions when compared to controls. 
Treatment with 1 and 10μm DMXB-A also significantly increased fluorescence for both 
regions when compared to controls. Treatment with 3μm DMXB-A in NMDA exposed 





































Fig. 8: PI uptake expressed as percent control in the Dentate Gyrus and CA3 in 
ETOH+NMDA exposed slices during EWD, treated with four levels of DMXB-A (0, 1, 
3, and 10 μm). Exposure to ETOH+NMDA alone and ETOH+NMDA slices treated with 
3 and 10μm DMXB-A did not significantly differ from control slices. When treated with 
1μm DMXB-A, NMDA exposed slices decreased in fluorescence compared to controls. 











DMXB-A’s Role in Reducing Toxicity during EWD  
In this study, toxicity in PND8 hippocampal slices undergoing various challenges 
were examined. These challenges included EWD after 10 day chronic binge-like 
exposure to 100mM ETOH in the presence or absence of an NMDA challenge, NMDA 
challenge alone, and the effect of various doses of DMXB-A on these groups and in 
healthy untreated slices. In support of the hypothesis, and in agreement with previous 
work using DMXB-A, our results suggest that DMXB-A may be neuroprotective against 
excitotoxicity associated with EWD during an NMDA challenge. This effect was seen in 
both males and females at all three concentrations of DMXB-A. The fact that DMXB-A 
reduced this toxicity was not surprising because of previous research supporting the role 
of the nicotinic system (and in many cases the α-7 nAChR) in protecting against various 
forms of cellular damage including GLU/NMDA toxicity, EWD related toxicity, β-
amyloid toxicity, and hypoxia (Akaike et al., 1994; Dajas-Bailador et al., 2000; Kihara et 
al., 1997; Hejmadi et al., 2003; Marin et al., 1994; Prendergast et al., 2001 A & B). 
Previous studies using DMXB-A have also found similar results; where toxicity induced 
by GLU/NMDA or ETOH/EWD is reduced by treatment with DMXB-A (de Fiebre et al., 
2003; Li. et al., 1999 A & B, 2000 & 2002; Shimohama et al., 1997).  
After investigating the effect of EWD without NMDA challange, it was found 
that EWD alone did not produce significant amounts of toxicity. This finding was not 
surprising and has been supported previously, where 24 hour EWD alone produced 
significantly less toxicity than slices treated with ETOH given an NMDA challenge 
(Wilkins et al., 2006). However, the level of ETOH used in this study was actually quite 
high, averaging about 65mM (roughly equivalent to 299 mg/dl) ETOH over the 10 day 
exposure period (Prendergast et al., 2004). This minimal toxicity is thought to occur 
because of insufficient glutamate levels in cultured hippocampi during EWD (Wilkins et 
al., 2006). In-vivo glutamate levels actually increase during EWD (Dahchour & De 
Witte, 1999) so, NMDA was used to induce toxicity during EWD in this model because, 
as described above, most of the toxicity caused by EWD is thought to be mediated by 
overexcitation of the NMDA type glutamatergic receptor (for review see Tsai et al., 
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1998; Kalluri et al., 1998; Grant et al., 1990; Eckardt et al., 2006; or Prendergast et al., 
[2001a and b]). NMDA induced toxicity in the absence of ETOH was also observed in 
the current study. Many previous studies (discussed above) use glutamatergic/NMDA 
insult to produce excitotoxicity without the presence of ETOH/EWD in various models of 
cellular culture, including OHSC (Akaike et al., 1994; Dajas-Bailador et al., 2000; 
Prendergast et al., 2001 A & B; Lewis et al., 2012). Yet, in the presence of ETOH, this 
toxicity caused by the addition of NMDA during EWD is thought to be multiplicative 
(greater than that of ETOH, or NMDA alone) (Wilkins et al., 2006), and is demonstrated 
in other studies from this lab (Lewis et al., 2012). However, this effect was only observed 
in females in our study, where NMDA alone produced a modest increase in toxicity and 
the addition of NMDA during EWD was significantly more toxic than NMDA alone. 
Surprisingly, in males, this did not occur and NMDA alone appeared to be more toxic 
than the addition of NMDA during EWD. 
Of the previous studies in this lab using male and female slices in an OHSC 
model (Barron et al., 2008 and Lewis et al., 2012) looking into NMDA or EWD related 
toxicity, there were not any reported significant differences between sexes to these insults 
alone. Yet, modulators of the NMDA receptor (i.e. spermidine) that enhance NMDAR 
function, have been shown to produce a greater amount of toxicity in females than males 
in the CA3 region of the hippocampus (Barron et al., 2008). This toxicity was negated by 
an NMDA antagonist ifenprodil, to significantly below control levels in females. This 
data was supported by Prendergast and colleagues (2000) who showed similar results in 
the CA3 region of the hippocampus. Other work using adenosine antagonists during 
ethanol withdrawal have found that granule cells of the dentate gyrus, and pyramidal cells 
in the CA3 and CA1 in females showed increased toxicity compared to males (Butler et 
al., 2008 & 2009). This toxicity from adenosine receptor antagonism was postulated to 
occur via a NMDAR mediated over activation because co-administration of MK-801 
(NMDAR antagonist) reduced this toxicity. These studies indicate that there may be 
differences between males and females in regard to NMDA and EWD mediated toxicity, 
but the differences found in these previous studies do not parallel those found in the 
current study.  These results and previous findings support a role of sex in the outcome of 
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ETOH/EWD and or NMDA toxicity, though it is obvious further work needs to be 
conducted to further elucidate these differences. 
After treating the slices with various levels of DMXB-A, it was found that the 
drug could be potentially toxic at higher doses, and in the presence of ETOH alone, could 
be protective against normal culture toxicity. First, the increased PI uptake in both sexes 
for the CA1, DG, and CA3 in control hippocampal slices when treated with all three 
concentrations of DMXB-A (1, 3, and 10μm) suggest that DMXB-A may be potentially 
toxic with the concentrations used in this study. At the lowest concentration of DMXB-A 
(1μm), the toxicity was reduced to near control levels in the CA1 without reducing the 
neuroprotective qualities of the drug in slices exposed to both ETOH and NMDA. These 
results were unexpected because toxicological reports in human clinical trials using 
DMXB-A have found that the drug is well-tolerated and safe (for review see Kem et al., 
2006). However, Li and colleagues (1999) found that acute administration with high 
levels (30μm) of DMXB-A could cause toxicity. This characteristic could be a result of 
the drug’s potential partial-agonist actions on the α-7 nAChR’s (reviewed in Kem, 2006). 
In fact, in Li’s (1999) study, they hypothesized that this toxicity is produced by a rapid 
desensitization of α-7 nAChR’s in response to high levels of DMXB-A, and that lower 
doses would pro-long receptor activation and cause neuroprotection. However, Treinin 
and colleagues (1995) found that in a non-desensitizing mutated form of the α-7 receptor 
there was reduced cellular viability in response to calcium overload.  And other studies 
have shown that using small amounts of selective α-7 antagonists (MLA) can produce 
some minor neuroprotection (Li. 1999). So there seems to be an ideal amount of receptor 
activation that promotes neuroprotection and not neurotoxicity. This interaction is unique 
because this same pattern of toxicity is seen in ETOH slices. Again, ETOH alone did not 
produce any significant amounts of toxicity, but when ETOH slices were treated with 
higher levels of DMXB-A (3 or 10 μm) significant levels of toxicity was observed in all 
three regions of the hippocampus treated with ETOH. Also, like in control slices, the 
lowest dose (1μm) of DMXB-A in ETOH slices reduced toxicity to below control levels, 
and actually produced a significant reduction of toxicity below control slices in the CA3 
and DG.  Though toxicity levels in control slices treated with 1μm DMXB-A were not 
significantly different from un-treated “healthy”  slices, they still displayed significantly 
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more toxicity than ETOH slices treated with 1μm DMXB-A.  This could possibly mean 
that modulation of the α-7 nAChR in a state of challenge (i.e. EWD) is crucial for its 
protective abilities, and that activation of this receptor in healthy cells is potentially toxic. 
Even more interesting though, is that DMXB-A when administered with the combination 
of ETOH and an NMDA challenge, reduced toxicity to near control levels at all three 
doses (1, 3, and 10μm); and that treatment with DMXB-A after NMDA challenge alone 
did not reduce toxicity to control levels at any concentration of the drug. These were a 
series of surprising findings that had not been previously observed. Because DMXB-A 
was only neuroprotective against EWD + NMDA induced toxicity, but not NMDA alone, 
and the fact that both forms of toxicity are thought to work in the same way (e.g. calcium 
toxicity),  it appears that there is a crucial mechanism that exists between the α-7 nAChR, 
EWD, and NMDA that does not occur otherwise. It may support the idea that DMXB-A 
is acting as a partial-agonist at the α-7 nAChR, but this relationship seems to be much 
more complex involving several mechanisms that may or may not directly involve the 
NMDA receptor in protection against EWD induced toxicity.   However, this process 
remains unclear and further research is needed to determine the NMDA receptors role in 
this process. 
Limitations and Future Directions 
In this study we showed that DMXB-A protects against EWD induced toxicity 
during an NMDA challenge in the hippocampi of PND 8 male and female rats. Future 
studies could address some potential limitations of this study. It is possible that the 
underlying mechanism of action of DMXB-A is not solely due to its action on α-7 
nAChR activity since DMXB-A could have effect on other ionotropic transmembrane 
receptors (as discussed above).  This question could be addressed by using more highly 
selective α-7 nAChR antagonists (like MLA & α-BTX) in the presence of DMXB-A. 
Previous studies (as described above) using this method have found that DMXB-A’s 
neuroprotective effects were negated by the use of selective α-7 nAChR antagonists such 
as (MLA and α-BTX) (refer to De-Fiebre et al., 2003; Li. et al., 1999, 2000 & 2002; 
Shimohama et al., 1997), the use of these drugs in our model would provide further 
evidence of the α-7 nAChR’s involvement in reducing toxicity induced by EWD. 
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However, it is also unclear if direct activation of the α-7 nAChR mediates the actions of 
other neurotransmitter systems to prevent cellular toxicity. It is thought that EWD and 
NMDA produce toxicity in a similar manner (Wilkins et al., 2006), but the current 
findings showed that DMXB-A was only able to reduce toxicity when NMDA and EWD 
was combined, but not from NMDA challenge alone. It is crucial to investigate the role 
of the NMDA receptor in this model using DMXB-A. One possible route could be to 
selectively antagonize the NMDA receptor to see if DMXB-A’s toxic and protective 
actions persist after NMDA has been taken out of the equation. Other neurotransmitters 
systems found in the hippocampus have been implicated in the α-7 nAChR’s protective 
actions.  It has been hypothesized that a reduction in symptoms associated with 
schizophrenia and the toxicity of β-amyloid is associated with the mediation of GABA-A 
receptors on hippocampal interneurons by the α-7 nAChR (Benes, 2012; Miwa et al., 
2011). Evidence for this modulation comes from research showing that activation of the 
α-7 nAChR increases GABA-A transmission in cultured hippocampal cells (Arnaiz et al., 
2008) and that activation of these  receptors can be protective against various forms of 
cell death and toxicity (Paula-Lima et al., 2005; Rosato-Siri et al., 2006; Miwa et al., 
2011).  Modulation of these GABA’ergic interneurons in our model could possibly be 
mediating the protective effect of DMXB-A against EWD toxicity during NMDA 
challenge. This hypothesis could be tested by co-administration of DMXB-A and 
selective GABA-A antagonists during EWD during an NMDA challenge. If DMXB-A’s 
protective effects are indeed mediated through activation of GABA’ergic interneurons, 
then a GABA-A antagonist would negate DMXB-A’s protective effects. Other 
possibilities to investigate the outcomes of DMXB-A treatment is the use of 
immunohistochemical techniques using compounds like NeuN to investigate neuronal 
tissue survival. NeuN is a nuclear antigen that stains specifically for mature neurons, and 
could be used in combination with propidium iodide which stains any cell type that has a 
compromised membrane (Mullen et al., 1992; Riccardi & Nicoletti 2006). This could 
help inform us to whether DMXB-A is selectively rescuing neurons and if 




Previous work with both nicotinic agonists, and DMXB-A in both humans and 
animals have found that these drugs can be protective against behavioral deficits 
associated with various diseases and forms of toxicity (for review see Kem et al., 2000; 
Olincy & Stevens 2007).  Because of this, future in-vivo work with DMXB-A must be 
conducted. This work is important for testing the possible therapeutic effects of this drug 
in our third trimester model of ethanol exposure in rodents because of its current use in 
clinical trials to treat diseases like schizophrenia and Alzheimer’s disease (3 clinical trials 
in recruiting phase as of 2015; info gathered from clinicaltrials.gov). This increases 
DMXB-A’s translation potential, and makes it a promising candidate for further work in 
models of fetal ethanol exposure. Completing behavioral work with DMXB-A is 
necessary to further explore the possibly neuroprotective nature of DMXB-A.  Studies 
using this drug and other nicotinic compounds are critical to increase the understanding 














Albuquerque, E., Pereira, E., Alkondon, M., Rogers, S. (2009). Mammalian Nicotinic 
Acetylcholine Receptors: From Structure to Function. Phisiology Review; (89)73-
120.  
Alfonso-Loeches, S., & Guerri, C. (2011). Molecular and behavioral aspects of the 
actions of alcohol on the adult and developing brain. [Research Support, Non-
U.S. Gov't Review]. Crit Rev Clin Lab Sci, 48(1), 19-47. doi: 
10.3109/10408363.2011.580567 
Akaike, A., Y. Tamura, T. Yokota, et al. (1994). Nicotine-induced protection of cultured 
cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate 
cytotoxicity. Brain Res. 644: 181–187. 
Archibald, S. L., Fennema-Notestine, C., Gamst, A., Riley, E. P., Mattson, S. N., & 
Jernigan, T. L. (2001). Brain dysmorphology in individuals with severe prenatal 
alcohol exposure. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, 
U.S. Gov't, P.H.S.]. Dev Med Child Neurol, 43(3), 148-154. 
Arnaiz, J., Gonzales, J., Sobrado, M., Baldelli, P., Carbone, E., Garcia, A., Hernandez-
guijo, J. (2008). Allosteric Modulation of α7 Nicotinic Receptors Selectively 
Depolarizes Hippocampal Interneurons, Enhancing Spontaneuous GABAergic 
Transmission. European Hournal of Neuroscience, 22:1097-1110. 
Barron, S., Mulholland, P. J., Littleton, J. M., & Prendergast, M. A. (2008). Age and 
gender differences in response to neonatal ethanol withdrawal and polyamine 
challenge in organotypic hippocampal cultures. [Comparative Study Research 
Support, N.I.H., Extramural]. Alcohol Clin Exp Res, 32(6), 929-936. doi: 
10.1111/j.1530-0277.2008.00649.x 
Benes, F. (2012). Nicotinic Receptors and Functional Regulation of GABA Cell 




Berman, R. F. & Hannigan, J. H. (2000). Effects of Prenatal Alcohol Exposure on the 
Hippocampus: Spatial Behavior, Electrophysiology, and Neuroanatomy. 
Hippocampus, 10:94-110. 
Bishop, S., Gahagan, S., Lord, C. (2007). Re-examining the Core Features of Autism: A 
Comparison of Autism Spectrum Disorder and Fetal Alcohol Spectrum Disorder. 
Journal of Child Psychology and Psychiatry; 48:11, 1111-1121. 
Calhoun, F. & Warren, K. (2007). Fetal Alcohol Syndrome: Historical Perspectives. 
Neuroscience & Behavioral Reviews, 31(2), 168-171.  
Centers for Disease Control Prevention (2012). Alcohol Use and Binge Drinking Among 
Women of Childbearing Age-United States, 2006-2010. Morbidity and Mortality 
Weekly Report, 61:534-538 
Centers for Disease Control Prevention (2014). Fetal Alcohol Spectrum Disorders 
(FASDs). Retrieved From: http://www.cdc.gov/ncbddd/fasd/data.html 
Chasnoff, I., Wells, A., King, L. (2015). Misdiagnosis and Missed Diagnoses in Foster 
and Adopted Children With Prenatal Alcohol Exposure. Pediatrics, doi:10.1542 
Chen, L., Wang, H., Zhang, Z., Li, Z.,….& Chen, L. (2010). DMXB (GTS-21 
Amelorates the Cognitive Deficits in Beta Amyloid Injected Mice through 
Preventing the Dysfunction of Alpha 7 Nicotinic Receptor. Journal of 
Neuroscience Research. 88, 1784-1794.  
Clancy, B., Finlay, B., Darlington, R., Anand, K. (2007). Extrapolating Brain 
development from Experimental Species to Humans. Neurotoxicology, (28):931-
937 
Coe, J., Sidders, J., Riley, K., Waltermire, J., Hagerman, R. (2001). A Survey of 
Medication Responses in Children and Adolescents with Fetal Alcohol Syndrome. 
Mental Health Aspects Developmental Disabilities, (4):148-155. 
Concepcion, C., Davies, P., Ulloa, L. (2008). Alpha 7 Nicotinic Acetylcholine Receptor: 
A link between inflammation and neurodegeneration. Neuroscience and 
Behavioral Reviews, 32, 693-706. 
42 
 
Coutcher, J. B., Cawley, G., Wecker, L. (1992). Dietary Choline Supplementation 
Increases the Density of Nicotine Binding sites in Rat Brain. Pharmacology and 
Experimental Therapeutics, 262(3): 1128-1132. 
Dahchour, A & De Witte, P. (1999). Effect of Repeated Ethanol Withdrawal on 
Glutamate Microdialysate in the Hippocampus. Alcoholism clinical and 
experimental research, 23(10):1698-1703. 
Dajas-Bailador, F.A., P.A. Lima & S. Wonnacott. 2000. The alpha7 nicotinic 
acetylcholine receptor subtype mediates nicotine protection against NMDA 
excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent 
mechanism.Neuropharmacology 39: 2799–2807 
Davies, M. (2003). The role of GABA-A receptors in mediating the effects of alcohol in 
the central nervous system. Journal of Psychiatry and Neuroscience, retrieved 
from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC165791/ on 12/2/2013.  
Dani, J. A. (2001). Overview of Nicotinic Receptors and Their Roles in the Central 
Nervous System. Society of Biological Psychiatry, 49, 166-174.  
de Fiebre, N. C., & de Fiebre, C. M. (2003). α7 Nicotinic Acetylcholine Receptor-
Mediated Protection Against Ethanol-Induced Neurotoxicity. Alcohol, 31, 149-
153. 
de Fiebre, N. C., & de Fiebre C. M. (2005). α7 Nicotinic Acetylcholine Receptor 
Knockout Selectively Enhances Ethanol-, but not B-Amyloid-Induced 
Neurotoxicity. Neuroscience Letters, 373, 42-47. 
De Graaf-Peters, V. & Hadders-Algra, M. (2006). Ontogeny of the Human Central 
Nervous System: What is Happening When? Early Human Development, 
(82):257-266. 
de Jonge, W. J., Ulloa, L. (2007). The Alpha7 Nicotinic Acetylcholine receptor as a 
pharmacological target for inflammation. British Journal of Pharmacology. 151, 
915-929. 
Briggs, C., ….. & Arneric, S. (1997). Functional Characterization of the Novel Neuronal 
Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In-Vivo. 
Pharmacology Biochemistry and Behavior, 57(1):231-241. 
43 
 
Dobbing, J., & Sands, J. (1979). Comparative aspects of the brain growth spurt. Early 
Hum Dev, 3(1), 79-83.  
Doig, J., McLennan, J., Gibbard, W. (2007). Medication Effects on Symptoms of 
Attention-Deficit/Hyperactivity Disorder in Children with Fetal Alcohol 
Spectrum Disorders. Child and Adolescent Psychopharmacology. 18(4): 365-371.  
Driscoll, C. D., Streissguth, A. P., Riley, E. P. (1990).  Prenatal Alcohol Exposure: 
Comparability of Effects in Humans and Animal Models. Neurotoxicology and 
Teratology, 12:231-237. 
Eckardt, M. J., File, S. E, ….. & Tabakoff, B. (2006). Effects of moderate alcohol 
consumption on the central nervous system. Alcoholism., 22(5), 998-1040. Doi: 
10.1111/j.1530-0277.1998.tb03695.x 
Fabian-Fine, R., Skehel, P., Errington, M. L., Davies, H. A., Sher, E., Stewart, M. G., 
Fine, A. (2001). Ultrastructural Distribution of the α7 Nicotinic Acetylcholine 
Receptor Subunit in Rat Hippocampus. The Journal of Neuroscience, 
21(20):7993-8003. 
Ferchmin, P.A., D. Perez, V.A. Eterovic & J. de Vellis. (2003). Nicotinic receptors 
differentially regulate N-methyl-D-aspartate damage in acute hippocampal 
slices. J. Pharmacol. Exp. Ther. 305: 1071–1078. 
Freedman, R. (2014). α7-Nicotinic Acetylcholine Receptor Agonists for Cognitive 
Enhancement in Schizophrenia. The Annual Review of Medicine. 65:245-261. 
Fryer, S. L., Schweinsburg, B. C., Bjorkquist, O. A., Frank, L. R., Mattson, S. N., 
Spadoni, A. D., & Riley, E. P. (2009). Characterization of white matter 
microstructure in fetal alcohol spectrum disorders. [Research Support, N.I.H., 
Extramural]. Alcohol Clin Exp Res, 33(3), 514-521. doi: 10.1111/j.1530-
0277.2008.00864.x 
Gähwiler, B. H. (1981). Organotypic monolayer cultures of nervous tissue. J. 
Neuroscience Methods, 4; 329–342. 
Gahring, L., Meyer, E., Rogers, S. (2003). Nicotine-induced neuroprotection against N-
methyl-D-aspartic acid or beta-amyloid peptide occurs through independent 
mechanisms distinguished by pro-inflammatory cytokine. Journal of 
Neurochemistry; 87(5): 1125-1136. 
44 
 
Goodlett, C. R., Peterson, S. D. (1995). Sex Differences in Vulnerability to 
Developmental Spatial Learning Deficits Induced by Limited Binge Alcohol 
Exposure in Neonatal Rats. Neurobiology of Learning and Memory, 64;265-275. 
Goodlett, C. R., Johnson, T., B. (1997). Neonatal Binge Ethanol Exposure Using 
Intubation: Timing and Dose Effects on Place Learning. Neurotoxicology & 
Teratology, 19(6);435-446. 
Goodlett, C. R., Horn, K. H. (2001). Mechanisms of Alcohol-Induced Damage to the 
Developing Nervous System. Alcohol Research and Healt, 25(3):175-184.  
Goodlett, C. R., Horn, K. H., Zhou, F. C. (2005). Alcohol Teratogenesis: Mechanisms of 
Damage and Strategies for Inetervention. Experimental Biologucal Medicine. 
(230,6): 394-406. 
Grant, K., Valverius, P., Hudspith, M., Tabakoff, B. (1990). Ethanol Withdrawal Seizures 
and the NMDA Receptor Complex. European Journal of Pharmacology. 
(176):289-296. 
Guo, W., Crossey, E., Zhang, L., Zucca, S., George, O., Valenzuela, F. (2011). Alcohol 
Exposure Decreases CREB Binding Protein Expression and Histone Acetylation 
in the Developing Cerebellum. Plos One. DOI: 20.13671. 
Heaton, M. B., Swanson, D. J., Paiva, M., Walker, D. W. (1996). Influence of Prenatal 
Ethanol Exposure on Cholinergic Development in the Rat Striatum. The Journal 
of Comparative Neurology, 364:113-120. 
Hejmadi, M. V., Dajas-Bailador, F., Barns, S. M., Jones, B., & Wonnacott, S. (2003). 
Neuroprotection by Nicotine against Hypoxia-Induced Apoptosis in Cortical 
Cultures Involves Activation of Multiple Nicotinic Acetylcholine Receptor 
Subtypes. Molecular and Cellular Neuroscience, 24, 779-786. 
Doi:10.1016/S1044-7431(03)00244-6. 
Hoyme, H. E., May, P. A., Kalberg, W. O., Kodituwakku, P., Gossage, P., Trujiloo,…& 
Robinson, L. (2004). A Practical Clinical Approach to Diagnosis of Fetal Alcohol 




Hunt, P. S., Jacobson, S. E., & Torok, E. J. (2009). Deficits in trace fear conditioning in a 
rat model of fetal alcohol exposure: dose-response and timing effects. [Research 
Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Alcohol, 43(6), 
465-474. doi: 10.1016/j.alcohol.2009.08.004 
Hurst, R., Rollema, H., Bertrand, D. (2013). Nicotinic Acetylcholine Receptors: From 
Basic Science to Theraputics. Pharmacology & Theraputics; (137):22-54. 
Idrus, N. M., McGough, N. N., Riley, E. P., & Thomas, J. D. (2011). Administration of 
memantine during ethanol withdrawal in neonatal rats: effects on long-term 
ethanol-induced motor incoordination and cerebellar Purkinje cell loss. [Research 
Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Alcohol Clin 
Exp Res, 35(2), 355-364. doi: 10.1111/j.1530-0277.2010.01351.x 
Jones, K. L. (2011). The effects of alcohol on fetal development. [Review]. Birth Defects 
Res C Embryo Today, 93(1), 3-11. doi: 10.1002/bdrc.20200 
Jones, K. L., & Smith, D. W. (1973). Recognition of the fetal alcohol syndrome in early 
infancy. Lancet, 302(7836), 999-1001.  
Kalluri, H., Mehta, K., Ticku, M. (1998). Up-Regulation of NMDA Receptor Subunits in 
the Rat Brain Following Chronic Ethanol Treatment. Molecular Brain Research; 
58(2):221-224.  
Kelly, S. & Tran. T. D. (1997). Alcohol Exposure During Development Alters Social 
Recognition and Social Communication in Rats. Neurotoxicology and Teratology, 
19(5):383-389. 
Kelly, S. J., Day, N., Streissguth, A. P. (2000). Effects of Prenatal Alcohol Exposure on 
Social Behavior in Humans and other Species. Neurotoxicology and Teratology; 
22:143-149. 
Kem, W., Soti, F., Wildeboer, K.,...& Arias, H. R. (2006). The Nemertine Toxin 
Anabaseine and Its Derivative DMXBA (GTS-21): Chemical and 
Pharmacological Properties. Marine Drugs. 4:255-273. 
46 
 
Kem, W. R. (2000). The Brain α7 nicotinic receptor may be an important therapeutic 
target for the treatment of Alzheimers Disease: Studies with DMXBA (GTS-21). 
Behavioral Brain Research, 113:169-181. 
Kihara, T., Shimohama, S., Sawada, H., Kimura, J., Kume, T., Kochiyama, H., Maeda, 
T., Akaike, A. (1997) Nicotinic Receptor Stimulation Protects Neurons Against 
Beta-Amyloid Toxicity, Ann. Neurol. 42, 159–163. 
Kully-Martens, K., Denys, K., Treit, S., Tamana, S., & Rasmussen, C. (2012). A review 
of social skills deficits in individuals with fetal alcohol spectrum disorders and 
prenatal alcohol exposure: profiles, mechanisms, and interventions. [Review]. 
Alcohol Clin Exp Res, 36(4), 568-576. doi: 10.1111/j.1530-0277.2011.01661.x 
Lemoine, P., Harousseau, H., Borteyru, J. P., & Menuet, J. C. (2003). Children of 
alcoholic parents - Observed anomalies: Discussion of 127 cases (Reprinted from 
Quest Med, vol 8, pg 476-482, 1968). Therapeutic Drug Monitoring, 25(2), 132-
136. doi: Doi 10.1097/00007691-200304000-00002 
Levin, E. D, & Rezvani, A. H. (2000). Development of Nicotininc Durg Therapy for 
Cognitive Disorders. European Journal of Pharmacology. 393, 141-146. 
Doi:0014-2999/00 
Levin, E. (2002). Nicotinic Receptor Subtypes and Cognitive Function. Journal of 
Neurobiology; 53(4):633-640. 
Lewis, B., Wellmann, K. A., & Barron, S. (2007). Agmatine reduces balance deficits in a 
rat model of third trimester binge-like ethanol exposure. [Research Support, 
N.I.H., Extramural]. Pharmacol Biochem Behav, 88(1), 114-121. doi: 
10.1016/j.pbb.2007.07.012 
Lewis, B., Wellmann, K.A., Kehrberg, A.H., Carter, M.L., Baldwin, T., Cohen, M., 
Barron, S. (2011). Behavioral deficits and cellular damage following 
developmental ethanol exposure in rats are attenuated by CP-101,606, an 
NMDAR antagonist with uniqueNR2B specificity. Pharmacology, Biochemistry 
and Behavior, 100, 545-553. 
Li, Y., King, M. A., Meyer, E. M. (2000). Alpha7 Nicotinic Receptor-Mediated 
Protection Against Ethanol-Induced Oxidative Stress and Cytotoxicity in PC12 
Cells. Brain Research, 861, 165-167.  
47 
 
Li, Y., Meyer, E. M., Walker, D. W., Millard, W. J., He, Y., King, M. A. (2002). Alpha 7 
Nicotinic Receptor Activation Inhibits Ethanol-Induced Mitochondiral 
Dysfunction, Cytochrome C Release and Neurotoxicity in Primary Rat 
Hippocampal Neuronal Cultures. Journal of Neurochemistry, 81:853-858.  
Light, K. E., Serbus, D. C., Santiago,  M. (1989).  Exposure of Rats to Ethanol from 
Postnatal Days 4 to 8: Alterations of Cholinergic Neurochemistry in the Cerebral 
Cortex and Corpus Striatum at Day 20. Alcoholism, 13(1):29-35. 
Livy, D. J., Miller, E. K., Maier, S. E., & West, J. R. (2003). Fetal alcohol exposure and 
temporal vulnerability: effects of binge-like alcohol exposure on the developing 
rat hippocampus. [Comparative Study Research Support, U.S. Gov't, P.H.S.]. 
Neurotoxicol Teratol, 25(4), 447-458.  
Lloyd, G. K. & Williams, M. (2000). Neuronal Nicotinic Acetylcholine Receptors as 
Novel Drug Targets. Journal of Pharmacology and Experimental Theraputics. 
292, 461-467. Doi:0022-3565/00/2922-0561.  
Marin, P., M. Maus, S. Desagher, et al. (1994). Nicotine protects cultured striatal neurons 
against N-methyl-D-aspartate receptor-mediated 
neurotoxicity. Neuroreport 5: 1977–1980 
Mattson, S. N., Riley, E. P., Jernigan, T. L., Garcia, A., Kaneko, W. M., Ehlers, C. L., & 
Jones, K. L. (1994). A decrease in the size of the basal ganglia following prenatal 
alcohol exposure: a preliminary report. [Comparative Study Research Support, 
U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Neurotoxicol 
Teratol, 16(3), 283-289. 
Mattson, S. N., & Riley, E. P. (1998). A review of the neurobehavioral deficits in 
children with fetal alcohol syndrome or prenatal exposure to alcohol. [Research 
Support, U.S. Gov't, P.H.S. Review]. Alcohol Clin Exp Res, 22(2), 279-294.  
Mattson, S. N., Riley, E. P., Gramling, L., Delis, D. C., & Jones, K. L. (1998). 
Neuropsychological comparison of alcohol-exposed children with or without 
physical features of fetal alcohol syndrome. [Clinical Trial Comparative Study 
Research Support, U.S. Gov't, P.H.S.]. Neuropsychology, 12(1), 146-153.  
48 
 
Mattson, S. N., Roesch, S. C., Fagerlund, A., Autti-Ramo, I., Jones, K. L., May, P. A., . . 
. Riley, E. P. (2010). Toward a neurobehavioral profile of fetal alcohol spectrum 
disorders. [Evaluation Studies Multicenter Study Research Support, N.I.H., 
Extramural]. Alcohol Clin Exp Res, 34(9), 1640-1650. doi: 10.1111/j.1530-
0277.2010.01250.x 
Meyer, E. M., Tay, E.T., Papke, R.L., Meyers, C., Huang, G., and De Fiebre, C.M. 
(1997). Effects of 3-[2,4-dimethoxybenzylidene]anabaseine (DMXB) on rat 
nicotinic receptors and memory-related behaviors. Brain Res 768:49–56. 
Meyer, E.M., Kuryatov, A., Gerzanich, V., Lindstrom, J., Papke, R.L. (1998).Analysis of 
3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivityand activity at human 
and rat alpha-7 nicotinic receptors.J Pharmacol Exp Ther 287: 918–925. 
Miwa, J. M., Freedman, R., & Lester, H. A. (2011). Neural Systems Governed by 
Nicotinic Acetylcholine Receptors: Emerging Hypotheses. Neuron, 70, 20-33. 
Doi: 10.1016/jneuron.2011.03.014.  
Monk, B. R, Leslie, F. R., Thomas, J. D. (2012). The Effects of Perinatal Choline 
Supplementation on Hippocampal Cholinergic Development in Rats Exposed to 
Alcohol During the Brain Growth Spurt. Hippocampus, 22: 1750-1757. 
Mullen, R., Buck, C., & Smith, A. (1992). NeuN, a Neuronal Specific Nuclear Protein in 
Vertabrates. Development, 116:201-211. 
Nanri, M., Yamamoto, J., Miyake, H., Watanabe, H. (1998). Protective effect of GTS-21, 
a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia 
in gerbils. Journal of Pharmacology; 76(1):23-29.  
National Institute on Alcohol Abuse and Alcoholism. (2014) Moderate and Binge 
Drinking. Retreived from: http://www.niaaa.nih.gov/alcohol-health/overview-
alcohol-consumption/moderate-binge-drinking 
National Institute of Health. (2013) Fetal Alcohol Spectrum Disorders. Retrieved from: 
http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=27 
Nagahara, A. H., Handa, R. J. (1999). Fetal Alcohol-Exposed Rats Exhibit Differantial 
Response to Cholinergic Drugs on a Delay-Dependent Memory Task. 
Neurobiology of Learning and Memory, 72:230-243. 
49 
 
Nagahara, A. H., Handa, R. J. (1999). Loss of Nicotine-Induced Effects on Locomotor 
Activity in Fetal Alcohol-Exposed Rats. Neurotoxicology and Teratology. 
21(6):647-652. 
Nio, E., Kogure, K., Yae, T., Onodera, H. (1991). The Effects of Maternal Ethanol 
Exposure on Neurotransmission and Second Messenger Systems: A Quantitative 
Autoradiographic Study in the Rat Brian. Developmental Brain research, 62:51-
60. 
Noraberg, J., Poulsen, F. R.,….& Zimmer, J. (2005) Organotypic Hippocampal Slice 
Cultures for Studies of Brain Damage, Neuroprotection and Neurorepair. CNS & 
Neurological Disorders. 4, 435-452. 
Olney, J. W. (2004). Fetal alcohol syndrome at the cellular level. Addiction Biology, 
(2):137-149. 
Olincy, A., Stevens, K. E. (2007). Treating Schizophrenia with an Alpha7 Nicotinic 
Agonist, From Mice to Men. Biochemical Pharamcology, 74, 1192-1201. 
Olson, H. C., Oti, R., Gelo, J., & Beck, S. (2009). “Family Matters:” Fetal Alcohol 
Spectrum Disorders and The Family. Dev Disabil Res Rev, 15(3), 235-249. 
DOI: 10.1002/ddrr.65 
Paintner, A., Williams, A. D., & Burd, L. (2012). Fetal alcohol spectrum disorders-- 
implications for child neurology, part 1: prenatal exposure and dosimetry. 
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 
Review]. J Child Neurol, 27(2), 258-263. doi: 10.1177/0883073811428376 
Parada, E., Egea, J., Buendia, I., Negredo, P., Cunha, A., Cardoso, S., Soares, M., Lopez, 
M. (2013) The Microglial alpha-7-Acetylcholine Nicotinic Receptor is a Key 
element in Promoting Neuroprotection by Inducing Heme Oxygenase-1 via 
Nuclear Factor Erythroid-2-Related Factor 2. Antioxidants & Redox Signaling, 
19(11):1135-1148. 
Paula-Lima, A., De Felice, F., Brito-Moreira, J., Ferreira, S. (2005). Activation of 
GABA-A Receptors by Taurine and Muscimol Blocks the Neurotoxicity of β-




Pauly, J. R., Charriez, C. M., Guseva, M., V., & Scheff, S. W. (2004). Nicotinic Receptor 
Modulation for Neuroprotection and Enhancement of Functional Recovery 
Following Brain Injury or Disease. N.Y. Acad. Sci. 1035, 316-334. 
Doi:10.1196/annals.1332.019. 
Peadon, E., & Elliott, E. J. (2010). Distinguishing between attention-deficit hyperactivity 
and fetal alcohol spectrum disorders in children: clinical guidelines. 
Neuropsychiatr Dis Treat, 6, 509-515.  
Peng, Y., Kwok, K. H., Yang, P. H., et al. (2005) Ascorbic Acid Inhibits ROS 
Production, NF-kappa B Activation and Prevents Ethanol Induced Growth 
Retardation and Microencephaly. Neuropharmacology. (48):426-434. 
Prendergast, M. Harris, B., Mullholland, P., Blanchard, J., Gibson, D., Holley, R., & 
Littleton, J. (2004). Hippocampal CA1 Region Neurodegeneration Produced by 
Ethanol Withdrawal Requires Activation of Intrinsic Polysynaptic Hippocampal 
Pathways and Function of N-Methyl-D-Aspartate Receptors. Neuroscience, 
124:869-877. 
Prendergast, M. A., Harris, B. R., Mayer, S., Holley, R. C., Hauser, K.F., & Littleton, J. 
M. (2001a). Chronic nicotine exposure reduces Nmethyl-d-aspartate receptor–
mediated damage in the hippocampus without altering calcium accumulation or 
extrusion: evidence of calbindin-D28K overexpression. Neuroscience 102, 75–85. 
Prendergast, M. A., Harris, B. R., Mayer, S., Holley, R. C., Pauly, J.R., & Littleton, J. M. 
(2001b). Nicotine exposure reduces N-methyl-D-aspartate toxicity in the 
hippocampus: relation to distribution of theα7 nicotinic acetylcholine receptor 
subunit. Med Sci Monit 7, 1153–1160. 
Prendergast, M., Harris, B., Blanchard, J., Mayer, S., Gibson, A., Littleton, J. (2000). In 
Vitro Effects of Ethanol Withdrawal and Spermidine on Viability of 
Hippocampus From Male and Female Rat. Alcoholism: Clinical and Experimental 
Research, 24(12).1855-1861. 
Prendergast, M., Harris, B., Mayer, S., Littleton, J. (2000). Chronic, But not Acute, 
Nicotine Exposure Attenuates Ethanol Withdrawal-Induced Hippocampal 
51 
 
Damage in Vitro. Alcoholism: Clinical and Experimental Research, 24(10):1583-
1592.  
Pruett, D., Waterman, H., Caughey, A. (2013). Fetal Alcohol Exposure: Consequences, 
Diagnosis, and Treatmentl. Obstetrical and Gynecological Survery, 68:1, 62-69. 
Riccardi, C., Nicoletti, I. (2006). Analysis of Apoptosis by Propidium Iodide Staining and 
Flow Cytometry. Nature Protocol, 1(3):1258-1261. 
Riley, E. P., Barron, S., Melcer, T., & Gonzalez, D. (1993). Alterations in activity 
following alcohol administration during the third trimester equivalent in P and NP 
rats. [Research Support, U.S. Gov't, P.H.S.]. Alcohol Clin Exp Res, 17(6), 1240-
1246.  
Riley, E. P., Infante, M. A., & Warren, K. R. (2011). Fetal alcohol spectrum disorders: an 
overview. [Research Support, N.I.H., Extramural Review]. Neuropsychol Rev, 
21(2), 73-80. doi: 10.1007/s11065-011-9166-x 
Riley, E. P., & McGee, C. L. (2005). Fetal alcohol spectrum disorders: an overview with 
emphasis on changes in brain and behavior. [Research Support, N.I.H., 
Extramural Research Support, U.S. Gov't, P.H.S. Review]. Exp Biol Med 
(Maywood), 230(6), 357-365.  
Rodier, P. M. (1994). Vulnerable periods and processes during central nervous system 
development. [Review]. Environ Health Perspect, 102 Suppl 2, 121-124. 
Rosato-Siri, M., Cattaneo, A., Cherubini, E. (2006). Nictoine-induced enhancement of 
synaptic plasticity at CA3-CA1 synapses requires GABAergic Interneurons in 
Adult anti-NGF Mice. Physiology, 576(2):361-377. 
Shimohama, S., Greenwald, D. L., Shafron, D. H.,….Meyer, E. H. (1998). Nicotinic a 7 
receptors protect against glutamate neurotoxicity and neuronal ischemic damage. 
Brain Research, 779, 359-363.  
Shimohama, S. & T. Kihara. 2001. Nicotinic receptor-mediated protection against beta-
amyloid neurotoxicity. Biol. Psychiatry 49:233–239 
Sowell, E. R., Johnson, A., Kan, E., Lu, L. H., Van Horn, J. D., Toga, A. W., . . . 
Bookheimer, S. Y. (2008). Mapping white matter integrity and neurobehavioral 
correlates in children with fetal alcohol spectrum disorders. [Comparative Study 
52 
 
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. J 
Neurosci, 28(6), 1313-1319. doi: 10.1523/JNEUROSCI.5067-07.2008 
Smith, A. M., Wellmann, K. A., Lundblad, T. M., Carter, M. L., Barron, S., & Dwoskin, 
L. P. (2012). Lobeline attenuates neonatal ethanol-mediated changes in 
hyperactivity and dopamine transporter function in the prefrontal cortex in rats. 
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 
Neuroscience, 206, 245-254. doi: 10.1016/j.neuroscience.2011.11.018 
 Spottiswoode, B. S., Meintjes, E. M., Anderson, A. W., Molteno, C. D., Stanton, M. E., 
Dodge, N. C., . . . Jacobson, S. W. (2011). Diffusion tensor imaging of the 
cerebellum and eyeblink conditioning in fetal alcohol spectrum disorder. 
[Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 
Alcohol Clin Exp Res, 35(12), 2174-2183. doi: 10.1111/j.1530-
0277.2011.01566.x 
Stokowski, L. A. (2004). Fetal alcohol syndrome: new guidelines for referral and 
diagnosis. [News]. Adv Neonatal Care, 4(6), 324.  
Stoppini, L., Buchs, P. A., & Muller, D. (1991). A Simple Method for Organotypic 
Cultures of Nervous Tissue. Journal of Neuroscience Methods, 37, 173-182. 
Stratton, K. R. (1996). Fetal Alcohol Syndrome: Diagnosis, Epidemiology, Prevention 
and Treatment. National Academy Press.     
Streissguth, A.P., Landesman-Dwyer, S., Martin, J.C., Smith D.W. (1980). Teratogenic 
effects of alcohol in humans and laboratory animals. Science, 209:353-61. 
Thomas, J.D., Weinert, S.P., Sharif, S., Riley, E.P. (1997). MK-801 Administration 
During Ethanol Withdrawal in Neonatal Rat Pups Attenuates Ethanol-Induced 
Behavioral Deficits. Alcoholism: Clinical and Experimental Research, 
21(7):1218-1225. 
Thomas, J.D. & Riley, E.P. (1997). Fetal Alcohol Syndrome: Does Alcohol Withdrawal 
Play a Role? Alcohol Health & Research World, 22:47-53. 
Thomas, J. D., Abou, E. J., & Dominguez, H. D. (2009). Prenatal choline 
supplementation mitigates the adverse effects of prenatal alcohol exposure on 
53 
 
development in rats. [Research Support, N.I.H., Extramural]. Neurotoxicol 
Teratol, 31(5), 303-311. doi: 10.1016/j.ntt.2009.07.002 
Thomas, J. D., Garrison, M., O’Neill, T. M. (2004). Perinatal Choline Supplementation 
Attenuates Behavioral Alterations Associated with Neonatal Alcohol Exposure in 
Rats. Neurotoxicology and Teratology, 26: 35-45.  
Thomas, J. D., Biane, J. S., O'Bryan, K. A., O'Neill, T. M., & Dominguez, H. D. (2007). 
Choline supplementation following third-trimester-equivalent alcohol exposure 
attenuates behavioral alterations in rats. [Comparative Study Research Support, 
N.I.H., Extramural]. Behav Neurosci, 121(1), 120-130. doi: 10.1037/0735-
7044.121.1.120 
Timmerman, D. B., Gronlein, J. H., Hohlhaas, K. L., Neilsen, E. O.,…..Olsen, G. M. 
(2007). An Allosteric Modulator of the Alpha7 Nicotinic Acetylcholine Receptor 
Possessing Cognition-Enhancing Properties in Vivo. Pharmacology and 
Experimental theraputics, 323(1), 294-307. 
Tiwari, V., Arora, V., & Chopra, K. (2012). Attenuation of NF-kappabeta mediated 
apoptotic signaling by tocotrienol ameliorates cognitive deficits in rats postnatally 
exposed to ethanol. Neurochem Int, 61(3), 310-320. doi: 
10.1016/j.neuint.2012.05.010 
Tizabi, Y., Al-Namaeh, M., Manaye, K., Taylor, R. (2003). Protective Effects of Nicotine 
on Ethanol-Induced Toxicity in Cultured Cerebellar Granuale Cells. Neurotoxicity 
Research. 5(5); 315-321.  
Tsai, G., & Coyle, J. T. (1998). The role of glutamatergic neurotransmission in the 
pathophysiology of alcoholism. Annual Reviews of Medicine, 49, 173-184. Doi: 
10.1146/annurev.med.49.1.173. 
Tran, T. D., Cronise, K., Marino, M. D., Jenkins, W. J., Kelly, S. (2000). Critical Periods 
for the effects of Alcohol Exposure on Brain Weight, Body Weight, Activity and 
Investigation. Behavioral Brain Research; 166:99-110. 
Tran, T. D. & Kelly, S. J. (2003). Critical Periods for Ethanol-Induced Cell loss in the 
Hippocampal Formation. Neurotoxicology and Teratology: 25:519-528 
54 
 
Treinin, M., Chalfie, M. (1995). A Mutated Acetylcholine Receptor Subunit Causes 
Neuronal Degeneration in C. Elegans. Neuron, 14:871-877. 
Wellmann, K., Lewis, B., & Barron, S. (2010). Agmatine reduces ultrasonic vocalization 
deficits in female rat pups exposed neonatally to ethanol. [Research Support, 
N.I.H., Extramural]. Neurotoxicol Teratol, 32(2), 158-163. doi: 
10.1016/j.ntt.2009.11.005 
West, J. R., Chen, W. A., Pantazis, N. J. (1994). Fetal Alcohol Syndrome: The 
Vulnerability of the Developing Brain and Possible Mechanisms of Damage. 
Metabolic Brain Disease; 9(4)291-322. 
Wilkins, L. H., Jr., Prendergast, M. A., Blanchard, J., Holley, R. C., Chambers, E. R., & 
Littleton, J. M. (2006). Potential value of changes in cell markers in organotypic 
hippocampal cultures associated with chronic EtOH exposure and withdrawal: 
comparison with NMDA-induced changes. [Comparative Study Research 
Support, N.I.H., Extramural]. Alcohol Clin Exp Res, 30(10), 1768-1780. doi: 
10.1111/j.1530-0277.2006.00210.x 
Wilkemeyer, M. F., Sebastian, A. B., Smith, S. A., et al. (2000). Antagonists of Alcohol 
Inhibition of Cell Adhesion. Proc Natl Acad Sci U S A. (97):3690-3695 
Wu, J., Lukas, R. (2011). Naturally-expressed Nicotinic Acetylcholine Receptor 
Subtypes. Biochemical Pharmacology; (82):800-807. 
Yangxin, L., Meyer, E. M., Walker, D. W., Millard, W. J., He, Y., & King, M. A. (2002) 
Alpha7 nicotinic receptor activation inhibits ethanol-induced mitochondrial 
dysfunction, cytochrome c release and neurotoxicity in primary rat hippocampal 








Curriculum Vitae  
Logan James Fields 




University of Kentucky, Lexington, KY. August 2012-Present 
Behavioral Neuroscience and Psychopharmacology, Psychology.  
Current GPA: 3.92/4 
Passed Thesis Defense May 2015 
 
Bachelor of Science, Psychology, May 2012 
Major GPA: 3.48/4.0 
General GPA: 3.48/4.0  
Purdue University, Indianapolis, IN 
 
Publications: 
Lutz, J.A., Carter, M.L., Fields, L., Barron, S., & Littleton, J.M. Altered relation between 
lipopolysaccharide-induced inflammatory response and excitotoxicity in rat organotypic 
hippocampal slice cultures during ethanol withdrawal. Alcoholism Clinical and 
Experimental Research. May 2015; 39(5): 827-835 
Lutz, J. A., Carter, M. L., Fields, L., Barron, S., & Littleton, J.M. The dietary flavonoid 
rhamnetin inhibits both inflammation and excitotoxicity during ethanol withdrawal in rat 
organotypic hippocampal slice cultures. Alcoholism Clinical and Experimental Research. 
September 2015.  




Carter, M.L., Lewis B., Wellmann, K.A., Fields, L., Hawkey, A., Littleton, J.M., & 
Barron, S. Pre-exposure to ethanol sensitizes the developing brain to a mild hypoxic 
challenge. Submitted to Alcoholism Clinical and Experimental Research. 
 
Presentations and Abstracts: 
 
Fields, L., Cruse, M., Carter, M., Barron, S. DMXB-A’s Effects on Spatial Learning and 
Balance Deficits in a Third Trimester Ethanol Exposure Paradigm. June 2015 (San 
Antonio, TX). 
 
Fields, L., Carter, M., Hawkey, A., & Barron, S. Neuroprotective effects of DMXB-A 
against Ethanol Withdrawal in Neonatal Rodent Models. April 2015 (Lexington, KY). 
 
Fields, L., Carter M.L, Hawkey, A., Lutz, J.A., Kem, W.E., Barron, S., DMXB-A 
reduces cell damage following developmental ETOH exposure in a rodent hippocampal 
slice model. Research Society on Alcoholism. June 2014 (Seattle, WA). 
 
Fields, L., Carter, M.L., Hawkey, A., Kem, W.E., & Barron, S. Dimethoxybenzylidene 
(DMXB) reduces balance deficits following “3rd trimester” ethanol exposure in female 
but not male rats. Alcoholism: Clinical and Experimental Research 37: (Suppl 2) 400a. 
 
Carter, M.L., Fields, L., Hawkey A., Littleton, J.M., Barron, S. The effects of NMDA 
receptor modulation following developmental ethanol and hypoxia exposure. Presented at 
the Research Society on Alcoholism. June 2014 (Seattle, WA). 
 
Carter, M.L., Nall, D., Fields, L., Hawkey, A., & Barron, S. The combination of ETOH 
and hypoxia produces behavioral deficits in a 3rd trimester rodent model. Presented at the 
Research Society on Alcoholism, June 2013 (Orlando, FL). Alcoholism: Clinical and 




Hawkey, R. Gupta, M. Carter, L. Fields & S. Barron. Effects of Developmental Alcohol 
Exposure in the Absence of Sensory Pre-Exposure on Adolescent Drinking Habits in 
Rats. Research Society on Alcoholism (2014). 
 
Hawkey, R. Gupta, M. Carter, L. Fields & S. Barron. Sex differences in body weight and 
ethanol consumption in adolescent rats. SEBA (2014). 
 
Hawkey, R. Gupta, M. Carter, L. Fields & S. Barron. Exploring the effects of 
developmental alcohol exposure in the absence of sensory preexposure on adolescent 
drinking habits in rats. Children at Risk Research Conference. June 2014 (Seattle, WA). 
 
Hawkey, W. Xu, H. Li, M. Carter, L. Fields, J. Luo, G. Chen, & S. Barron. 
Consequences of Prenatal Drinking in the Dark(DID) and Neonatal Ethanol Intubation on 
Exploration in Juvenile Mice.  Research Society on Alcoholism. June 2015 (San Antonio, 
TX) 
 
A. Hawkey, W. Xu, H. Li, M. Carter, L. Fields, J. Luo, G. Chen, & S. Barron. 
Behavioral Deficits in a Novel “3 trimester” Mouse Model of Developmental Alcohol 





Fields, L. “The nAChR Agonist DMXB-A’s Effects on a Third Trimester Ethanol 
Exposure Model: a behavioral approach.” Behavioral Neuroscience and 
Psychopharmacology Departmental Brown Bag, September 2014. 
 
Fields, L., Carter, M., Hawkey, A. “In vitro/In Vivo Methods to investigating Fetal 
Ethanol Effects in the Barron lab.” Behavioral Neuroscience and Psychopharmacology 




Fields, L. “Neuroprotective effects of DMXB-A against ethanol withdrawal in neonatal 
rodent models.” Behavioral Neuroscience and Psychopharmacology Departmental Brown 
Bag, March 2014. 
 
Fields, L. “The Baby and the Bottle.” Brain Outreach Program at Bryan Station High 






 place poster at the 3
rd




Fall 2015: Teaching Assistant and Lab Leader for Learning Psy-450 (U. of Kentucky)  
Fall 2014: Teaching  Assistant and lab leader for Behavioral Neuroscience PSY-456 (U. 
of Kentucky) 
Fall 2014: Guest Lecturer for Behavioral Neuroscience PSY 456 for Dr. Michael Bardo 






Fall 2015: Created a student Study Aide Coloring Book modeling the sheep, rodent, and 
human brain for the advanced lecture lab in behavioral neuroscience PSY-456 
Fall 2015: Developed course material for a student lab manual for the advanced lecture 
lab in behavioral neuroscience 
Fall 2014 & 2015: Participated in Career Day at Yates Elementary School (information 
and education about psychology and neuroscience as a career). 
Summer 2014 & 2015: Volunteered Audio/Visual Aide for the Research Society on 
Alcoholism annual meeting 
59 
 
Spring 2014: Brain Day outreach program at Veteran’s Park Elementary School 
Spring 2014: Abstract Reviewer and Moderator for National Conferences on 
Undergraduate Research (NCUR) 
Spring 2014: Brain outreach program at Bryan Station High School  
Fall 2014: Graduate Student Ambassador at Graduate School Night at Transylvania 
University  
Spring 2013: Won first place poster at Fourth Annual Children at Risk Research 
Conference, U of Kentucky.  
Fall 2013- Spring 2014: Behavioral Neuroscience and Psychopharmacology department 
seminar organizer  
Multiple Deans Lists. 
 
 
 
 
 
